WO2008117062A1 - Bioeffective krill oil compositions - Google Patents

Bioeffective krill oil compositions

Info

Publication number
WO2008117062A1
WO2008117062A1 PCT/GB2008/001080 GB2008001080W WO2008117062A1 WO 2008117062 A1 WO2008117062 A1 WO 2008117062A1 GB 2008001080 W GB2008001080 W GB 2008001080W WO 2008117062 A1 WO2008117062 A1 WO 2008117062A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
krill
oil
embodiments
composition
fatty
Prior art date
Application number
PCT/GB2008/001080
Other languages
French (fr)
Inventor
Inge Bruheim
Mikko Griinari
Snorre Tilseth
Sebastiano Banni
Jeffrey Cohn
Daniele Mancinelli
Original Assignee
Aker Biomarine Asa
Golding, Louise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL AND VEGETABLE OILS, FATS, FATTY SUBSTANCES AND WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11BPRODUCING (PRESSING, EXTRACTION), REFINING AND PRESERVING FATS, FATTY SUBSTANCES (e.g. LANOLIN), FATTY OILS AND WAXES, INCLUDING EXTRACTION FROM WASTE MATERIALS; ESSENTIAL OILS; PERFUMES
    • C11B3/00Refining fats or fatty oils
    • C11B3/006Refining fats or fatty oils by extraction
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/612Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05KPRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extract the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obatined are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti- inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Description

BIOEFFECTIVE KRILL OIL COMPOSITIONS

FIELD OF THE INVENTION

This invention relates to extracts from Antarctic krill that comprise bioactive fatty acids.

BACKGROUND OF THE INVENTION

In the Southern Ocean, off the coast of Antarctica, Antarctic krill (Euphausia superba) can be found in large quantities, ranging from 300-500 million metric tons of biomass. It feeds on phytoplankton during the short Antarctic summer. During winter, however, its food supply is limited to ice algae, bacteria, marine detritus as well as depleting body protein for energy.

In order to isolate the krill oil from the krill, solvent extraction methods have been used. See, e.g., WO 00/23546. Krill lipids have been extracted by placing the material in a ketone solvent (e.g. acetone) in order to extract the lipid soluble fraction. This method involves separating the liquid and solid contents and recovering a lipid rich fraction from the liquid fraction by evaporation. Further processing steps include extracting and recovering by evaporation the remaining soluble lipid fraction from the solid contents by using a solvent such as ethanol. See, e.g., WO 00/23546. The compositions produced by these methods are characterized by containing at least 75 μg/g astaxanthin, preferably 90 μg/g astaxanthin. Another krill lipid extract disclosed contained at least 250 μg/g canastaxanthin, preferably 270 μg/g canastaxanthin.

Krill oil compositions have been described as being effective for decreasing cholesterol, inhibiting platelet adhesion, inhibiting artery plaque formation, preventing hypertension, controlling arthritis symptoms, preventing skin cancer, enhancing transdermal transport, reducing the symptoms of premenstrual symptoms or controlling blood glucose levels in a patient. See, e.g., WO 02/102394. In yet another application, a krill oil composition has been disclosed comprising a phospholipid and/or a flavonoid. The phospholipid content in the krill lipid extract could be as high as 60% w/w and the EPA/DHA content as high as 35% (w/w). See, e.g., WO 03/011873.

Furthermore, nutraceuticals, pharmaceuticals and cosmetics comprising the phospholipid extract were disclosed. Previously, it was also shown that supercritical fluid extraction using neat CO2 could be used to prevent the extraction of phospholipids in order to extract the neutral lipid fraction from krill, which comprised of esterified and free astaxanthin. See, e.g., Yamaguchi et al., J. Agric. Food Chem. (1986), 34(5), 904-7. Supercritical fluid extraction with solvent modifier has previously been used to extract marine phospholipids from salmon roe, but has not been previously used to extract phospholipids from krill meal. See, e.g., Tanaka et al., J. Oleo Sci. (2004), 53(9), 417-424. The methods described above rely on the processing of frozen krill that are transported from the Southern Ocean to the processing site. This transportation is both expensive and can result in degradation of the krill starting material. Data in the literature showing a rapid decomposition of the oil in krill explains why some krill oil currently offered as an omega-3 supplement in the marketplace contains very high amounts of partly decomposed phosphatidylcholine and also partly decomposed glycerides. Saether et al., Comp. Biochem Phys. B 83B(I): 51-55 (1986). The products offered also contain high levels of free fatty acids. ■ ■ ' i

What is needed in the art are methods for processing krill that do not require transport of frozen krill material over long distances and the products produced by those methods.

SUMMARY OF THE INVENTION

In a first aspect of the invention is a composition characterized by comprising at least 65% (w/w) phospholipids.

In another aspect of the invention is a composition obtained from aquatic or marine sources, characterized by comprising 65% (w/w) phospholipids.

In yet another aspect of the invention is a composition obtained from krill, characterized by comprising at least 65% (w/w) phospholipids.

In another aspect of the invention is a composition obtained from krill, characterized by comprising at least 65% (w/w) phospholipids and at least 39% omega-3 fatty acids (w/w). In yet another aspect of the invention is a composition obtained from krill, characterized by comprising at least 65% (w/w) phospholipids, at least 39% omega-3 fatty acids (w/w) and at least 580 mg/kg astaxanthin esters.

In another aspect of the invention is a composition obtained from krill, characterized by comprising at least 39% omega-3 fatty acids (w/w) and at least 580 mg/kg astaxanthin esters.

In yet another aspect of the invention is a composition obtained from krill, characterized by comprising at least 65% (w/w) phospholipids and at least 580mg/kg astaxanthin esters. In yet another aspect, the present invention provides a krill oil effective for reducing insulin resistance, improving blood lipid profile, reducing inflammation or reducing oxidative stress.

In some embodiments, the present invention provides compositions comprising: from about 3% to 10% ether phospholipids on a w/w basis; from about 35% to 50% non-ether phospholipids on w/w basis, so that the total amount of ether phospholipids and non-ether phospholipids in the composition is from about 48% to 60% on a w/w basis; from about 20% to 45% triglycerides on a w/w basis; and from about 400 to about 2500 mg/kg astaxanthin. In some embodiments, the ether phospholipids are selected from the group consisting of alkylacylphosphatidylcholine, lyso-alkylacylphosphatidylcholine, alkylacylphosphatidylethanolamine, and combinations thereof. In some embodiments, the ether lipids are greater than 90% alkylacylphosphatidylcholine. In some embodiments, the non-ether phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and combinations thereof. In some embodiments, krill oil composition comprises a blend of lipid fractions obtained from krill. In some preferred embodiments, krill is Euphausia superba, although other krill species also find use in the present invention. Other krill species include, but are not limited to E. paciβca, E. frigida, E. longirostris, E. triacantha, E. vallentini, Meganyctiphanes norvegica, Thysanoessa raschii and Thysanoessa inermis. In some embodiments, the compositions comprise from about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the present invention provides a capsule containing the foregoing compositions.

In further embodiments, the present inventions provide compositions comprising: from about 3% to 10% ether phospholipids on a w/w basis; and from about 400 to about 2500 mg/kg astaxanthin. In some embodiments, the compositions further comprise from about 35% to 50% non-ether phospholipids on w/w basis, so that the total amount of ether phospholipids and non-ether phospholipids in the composition is from about 38% to 60% on a w/w basis. In some embodiments, the compositions further comprise from about 20% to 45% triglycerides on a w/w basis. In some embodiments, the ether phospholipids are selected from the group' consisting of alkylacylphosphatidylcholine, lyso-alkylacylphosphatidylcholine, alkylacylphosphatidylethanolamine, and combinations thereof. In some embodiments, the ether lipids are greater than 90% alkylacylphosphatidylcholine. In some embodiments, the non-ether phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and combinations thereof. In some embodiments, krill oil composition comprises a blend of lipid fractions obtained from krill. In some preferred embodiments, krill is Euphausia superba, although other krill species also find use in the present invention. Other krill species include, but are not limited to E. pacifica, E. frigida, E. longirostris, E. triacantha, E. vallentini, Meganyctiphanes norvegica, Thysanoessa raschii and Thysanoessa inermis. In some embodiments, the compositions comprise about

25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about

80% to 90% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the present invention provides a capsule containing the foregoing compositions.

In some embodiments, the present invention provides a composition comprising at least 65% (w/w) of phospholipids, said phospholipids characterized in containing at least 35% omega-3 fatty acid residues. In some preferred embodiments, the composition is derived from a marine or aquatic biomass. In some further preferred embodiments, the composition is derived from krill. In some embodiments, the composition comprises less than 2% free fatty acids. In some embodiments, composition comprises less than 10% triglycerides. In some preferred embodiments, the phospholipids comprise greater than 50% phosphatidylcholine. In some embodiments, the composition comprises at least 500 mg/kg astaxanthin esters. In some embodiments, the composition comprises at least 500 mg/kg astaxanthin esters and at least 36% (w/w) omega-3 fatty acids. In some embodiments, the composition comprises less than about 0.5g/100g total cholesterol. In some embodiments, the composition comprises less than about 0.45% arachidonic acid (w/w).

In some embodiments, the present invention provides a krill lipid extract comprising at least 500, 100, 1500, 2000, 2100, or 2200 mg/kg astaxanthin esters and at least 36% (w/w) omega-3 fatty acids. In further embodiments, the present invention provides a krill lipid extract comprising at least 100 mg/kg astaxanthin esters, at least 20% (w/w) omega-3 fatty acids, and less than about 0.45% arachidonic acid (w/w).1

In some embodiments, the present invention provides methods comprising administering the foregoing compositions to a subject in an amount effective for reducing insulin resistance, reducing inflammation, improving blood lipid profile and reducing oxidative stress. In some embodiments, the present invention provides a krill lipid extract comprising greater than about 80% triglycerides and greater than about 90, 100, 500, 1000, 1500, 200, 2100 or 2200 mg/kg astaxanthin esters, hi some embodiments, the krill lipid extract is characterized in containing from about 5% to about 15% omega-3 fatty acid residues. In some embodiments, the krill lipid extract is characterized in containing less than about 5% phospholipids. In some embodiments, the krill lipid extract is characterized in comprising from about 5% to about 10% cholesterol.

In some embodiments, the present invention provides a krill meal composition comprising less than about 50g/kg total fat. In some embodiments, the krill meal composition comprises from about 5 to about 20 mg/kg astaxanthin esters. In some embodiments, the krill meal composition comprises greater than about 65% protein. In some embodiments, the krill meal composition of comprises greater than about 70% protein. In some further embodiments, the present invention provides an animal feed comprising the krill meal composition. In some embodiments, the present invention provides methods of increasing flesh coloration in an aquatic species comprising feeding said aquatic species a composition comprising the krill meal described above. In some embodiments, the present invention provides methods of increasing growth and overall survival rate of aquatic species by feeding the krill meal described above. In some embodiments, the present invention provides methods of producing krill oil comprising: a) providing krill meal; and b) extracting oil from said krill meal. In some embodiments, the krill meal is produced by heat-treating krill. In some embodiments, the krill meal is stored prior to the extraction step. In some embodiments, the extracting step comprises extraction by supercritical fluid extraction. In some embodiments, the supercritical fluid extraction is a two step process comprising a first extraction step with carbon dioxide and a low concentration of a co-solvent (e.g., from about 1-10% co-solvent) and a second extraction step with carbon dioxide and a high concentration of a co-solvent (e.g., from about 10-30% co-solvent). In preferred embodiments, the co-solvent is a C1-C3 monohydric alcohol, preferably ethanol. In some embodiments, the present invention provides oil produced by the foregoing method.

In some embodiments, the present invention provides methods of production of krill oil comprising: a) providing fresh krill; b) treating said fresh krill to denature Upases and phospholipases in said fresh krill to provide a denatured krill product; and c) extracting oil from said denatured krill product. In some embodiments, the denaturation step comprises heating of said fresh krill. In some embodiments, the denaturation step comprises heating said fresh krill after grinding. In some embodiments, the methods further comprise storing said denatured krill product at room temperature or below between the denaturation step and the extraction step. In some embodiments, the enzyme denaturation step is achieved by application of heat. In some embodiments, the extraction step comprises use of supercritical carbon dioxide, with or without use of a polar modifier. In some embodiments, the extraction step comprises use of ethanol. In some embodiments, the extraction step is comprises ethanol extraction followed by acetone to precipitation of phospholipids. In some embodiments, the denatured krill product is a meal. In some embodiments, the present invention provides oil produced by the foregoing method.

In some embodiments, the present invention provides a composition comprising oil extracted from krill having a phosphatidylcholine content of greater then about 50% (w/w). In some embodiments, the oil has a phosphatidylcholine content of greater then about 70% (w/w). In some embodiments, the oil has a phosphatidylcholine content of greater then about 80% (w/w). In some embodiments, the composition comprises less than 2% free fatty acids. In some embodiments, the composition comprises less than 10% triglycerides. In some embodiments, the composition comprises at least 500 mg/kg astaxanthin esters, hi some embodiments, the composition comprises less than about 0.45% arachidonic acid (w/w).

In some embodiments, the present invention provides composition comprising odorless krill oil. In some embodiments, the odorless krill oil comprises less than about 10 mg/kg (w/w) trimethylamine. hi some further embodiments, the present invention provides an odorless krill oil produced by the method comprising: extracting a neutral krill oil from a krill oil containing material by supercritical fluid extraction to provide a deodorized krill material, wherein said neutral krill oil contains odor causing compounds and extracting a polar krill oil from said deodorized krill material by supercritical fluid extraction with a polar entrainer to provide an essentially odorless krill oil.

In some embodiments, the present invention provides a composition comprising krill oil containing less than about 70 micrograms/kilogram (w/w) astaxanthin esters. In some embodiments, the compositions comprise less than about 50 micrograms/kilogram (w/w) astaxanthin esters. In some embodiments, the compositions comprise less than about 20 micrograms/kilogram (w/w) astaxanthin esters. In some embodiments, the compositions comprise less than about 5 micrograms/kilogram (w/w) astaxanthin esters.

In some embodiments, the present invention provides a krill oil produced by the process comprising: pumping fresh krill from a trawl onto a ship, heating the krill to provide a krill material, and extracting oil from the krill material.

In further embodiments, the present invention provides a blended krill oil composition comprising: from about 45% to 55% w/w phospholipids; 'from about 20% to 45% w/w triglycerides; and from about 400 to about 2500 mg/kg astaxanthin. In some embodiments, the blended krill oil product comprises a blend of lipid fractions obtained from Euphausia superba. In some embodiments, the composition comprises from about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids.

In still other embodiments, the present invention provides a Euphausia superba krill oil composition comprising: from about 30% to 60% w/w phospholipids; from about 20% to

50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to

35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids.

In still further embodiments, the present invention provides a dietary supplement comprising encapsulated Euphausia superba krill oil comprising from about 30% to 60% w/w phospholipids; from about 20% to 50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the present invention provides methods of making a Euphausia superba krill oil composition comprising: contacting Euphausia superba with a polar solvent to provide a polar extract comprising phospholipids; contacting Euphausia superba with a neutral solvent to provide a neutral extract comprising triglycerides and astaxanthin; combining said polar extract and said neutral extract to provide Euphausia superba krill oil comprising from about 30% to 60% w/w phospholipids; from about 20% to 50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the methods further comprise the step of encapsulating the Euphausia superba krill oil. hi some embodiments, the present invention provides a Euphausia superba krill oil produced by the methods described above.

In some embodiments, the present invention provides methods of producing a dietary supplement comprising; contacting Euphausia superba with a polar solvent to provide an polar extract comprising phospholipids; contacting Euphausia superba with a neutral solvent to provide a neutral extract, comprising triglycerides and astaxanthin; combining said polar extract and said neutral extract to provide Euphausia superba krill oil comprising from about 30% to 60% w/w phospholipids; from about 20% to 50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids; and encapsulating said Euphausia superba krill oil.

In some embodiments, the present invention provides methods of reducing diet- induced hyperinsulinemia, insulin insensitivity, muscle mass hypertrophy, serum adiponectin reduction or hepatic steatosis comprising in a subject exposed to a high fat diet: administering to said subject exposed to a high fat diet an effective amount of a krill oil composition under conditions such that a condition selected from the group consisting of diet-induced hyperinsulinemia, insulin insensitivity, muscle mass hypertrophy, serum adiponectin reduction and hepatic steatosis is reduced. The present invention is not limited to any particular krill oil composition. In some embodiments, the krill oil composition is a Euphausia superba krill oil composition. The present invention is not limited to any particular formulation of krill oil. In some embodiments, the krill oil composition is encapsulated. In some preferred embodiments, the effective amount of a krill oil composition is from 0.2 grams to 10 grams of said krill oil composition. In some embodiments, the krill oil composition comprises: from about 45% to 55% w/w phospholipids; from about 20% to 45% w/w triglycerides; and from about 400 to about 2500 mg/kg astaxanthin. In some embodiments, the krill oil composition comprises a blend of lipid fractions obtained from Euphausia superba. In some embodiments, the krill oil composition comprises from about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids, hi some embodiments, the krill oil composition comprises from about 30% to 60% w/w phospholipids; from about 20% to 50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, and wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids.

In some embodiments, the present invention provides methods of reducing diet- induced hyperinsulinemia, insulin insensitivity, muscle mass hypertrophy, serum adiponectin reduction or hepatic steatosis comprising in a subject consuming a high fat diet or a normal fat diet: administering to said subject consuming a high fat diet or a normal fat diet an effective amount of a krill oil composition under conditions such that a condition selected from the group consisting of diet-induced hyperinsulinemia, insulin insensitivity, muscle mass hypertrophy, serum adiponectin reduction and hepatic steatosis is reduced. The present invention is not limited to any particular krill oil composition. In some embodiments, the krill oil composition is a Euphausia superba krill oil composition. The present invention is not limited to any particular formulation of krill oil. In some embodiments, the krill oil composition is encapsulated. In some preferred embodiments, the effective amount of a krill oil composition is from 0.2 grams to 10 grams of said krill oil composition. In some embodiments, the krill oil composition comprises: from about 45% to 55% w/w phospholipids; from about 20% to 45% w/w triglycerides; and from about 400 to about 2500 mg/kg astaxanthin. hi some embodiments, the krill oil composition comprises a blend of lipid fractions obtained from Euphausia superba. In some embodiments, the krill oil composition comprises from about 25% to 30% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the krill oil composition comprises from about 30% to 60% w/w phospholipids; from about 20% to 50% triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, and wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids. In some embodiments, the present invention provides methods of inducing diuresis in a subject comprising: administering to said subject an effective amount of a krill oil composition under conditions such that diuresis is induced. In some embodiments, the present invention provides methods of increasing muscle mass in a subject, comprising: administering to said subject an effective amount of a krill oil composition under conditions such that muscle mass is increased. In some embodiments, the present invention provides methods of decreasing protein catabolism in a subject, comprising: administering to said subject an effective amount of a krill oil composition under conditions such that protein catabolism is decreased. In some embodiments, the present invention provides methods of decreasing lipid content in the heart of a subject, comprising: administering to said subject an effective amount of a krill oil composition under conditions such that lipid content in the heart of the subject is decreased. In some embodiments, the present invention provides methods of decreasing lipid content in the liver of a subject, comprising: administering to said subject an effective amount of a krill oil composition under conditions such that lipid content in the liver of the subject is decreased.

DESCRIPTION OF THE FIGURES

Figure 1. 3 IP NMR analysis of polar lipids in krill oil.

Figure 2. Blood lipid profiles in Zucker rats fed different forms of omega-3 fatty acids (TAG = FO, PLl = NKO and PL2 = Superba). Figure 3. Plasma glucose concentration in Zucker rats fed different forms of omega-3 fatty acids.

Figure 4. Plasma insulin concentration in Zucker rats fed different forms of omega-3 fatty acids.

5 Figure 5. Estimated HOMA-IR values in Zucker rats fed different forms of omega-3 fatty acids.

Figure 6. The effect of dietary omega-3 fatty acids on TNFD production by peritoneal macrophages.

Figure 7. The effect of dietary omega-3 fatty acids on lipid accumulation in the liver. 10 Figure 8. The effect of dietary omega-3 fatty acids on lipid accumulation in the muscle.

Figure 9. The effect of dietary omega-3 fatty acids on lipid accumulation in the heart.

Figure 10. Relative concentrations of DHA in the brain in Zucker rats supplemented with omega-3 fatty acids.

, 15 Figure 11. Mean group body weights (g) in the collagen-induced male DB A/1 arthritic mice. B - PL2 is the krill oil group. * p<0.05, significantly different from Group A (Positive Control - Fish Oil) and Group C (Control).

Figure 12. Body weight for the various treatment groups.

Figure 13. Muscle weight for the various treatment groups. 20 . Figure 14. Muscle to body weight ratio for the various treatment groups.

Figure 15. Serum adiopnectin levels (ng/ml) for the various treatment groups.

Figure 16. Serum insulin levels for the various treatment groups.

Figure 17. Blood glucose (mmol/1) levels in the various treatment groups.

Figure 18. HOMA-IR values for the various treatment groups. 25 Figure 19. Liver triglyceride levels (μmol/g) for the various treatment groups.

DEFINITIONS

As used herein, "phospholipid" refers to an organic compound having the following 30 general structure:

wherein Rl is a fatty acid residue, R2 is a fatty .acid residue or -OH, and R3 is a -H or nitrogen containing compound choline (HOCH2CH2N+(CHS)3OH"), ethanolamine (HOCH2CH2NH2), inositol or serine. Rl and R2 cannot simultaneously be OH. When R3 is an -OH, the compound is a diacylglycerophosphate, while when R3 is a nitrogen-containing compound, the compound is a phosphatide such as lecithin, cephalin, phosphatidyl serine or plasmalogen.

An "ether phospholipid" as used herein refers to a phospholipid having an ether bond at position 1 the glycerol backbone. Examples of ether phospholipids include, but are not limited to, alkylacylphosphatidylcholine (AAPC), lyso-alkylacylphosphatidylcholine

(LAAPC), and alkylacylphosphatidylethanolamine (AAPE). A "non-ether phospholipid" is a phospholipid that does not have an ether bond at position 1 of the glycerol backbone.

As used herein, the term omega-3 fatty acid refers to polyunsaturated fatty acids that have the final double bond in the hydrocarbon chain between the third and fourth carbon atoms from the methyl end of the molecule. Non-limiting examples of omega-3 fatty acids include, 5,8,11,14,17-eicosapentaenoic acid (EPA), 4,7;10,13,16,19-docosahexanoic acid

(DHA) and 7,10,13,16,19-docosapentanoic acid (DPA).

As used herein, astaxanthin refers to the following chemical structure:

As used herein, astaxanthin esters refer to the fatty acids esterifϊed to OH group in the astaxanthin molecule.

As used herein, the term w/w (weight/weight) refers to the amount of a given substance in a composition on weight basis. For example, a composition comprising 50% w/w phospholipids means that the mass of the phospholipids is 50% of the total mass of the composition (i.e., 50 grams of phospholipids in 100 grams of the composition, such as an oil).

DETAILED DESCRIPTION OF THE INVENTION

This invention discloses novel krill oil compositions characterized by containing high levels of astaxanthin, phospholipids, included an enriched quantities of ether phospholipids, and omega-3 fatty acids. The krill oils compositions are extracted from krill meal using supercritical fluid extraction (SFE) with a co-solvent modifier. The krill meal has been processed on board a ship in Antarctica using live krill as starting material in order to ensure the highest possible quality of the krill meal. The krill oils are extracted from the krill meal in two stages, in step 1 the neutral fraction is extracted using neat supercritical CO2 or in combination with 5% ethanol. The neutral fraction consisted mostly of triglycerides and cholesterol. In stage 2, the polar lipids (phospholipids) are extracted by adding at least 20% ethanol to the supercritical CO2 extraction medium.

The present invention provides methods to avoid decomposition of glycerides and phospholipids in krill oil and compositions produced by those methods. The product obtained by these new methods is virtually free of enzymatically decomposed oil constituents. The solution to the problem is to incorporate a protein denaturation step on fresh krill prior to use of any extraction technology. Denaturation can be achieved by thermal stress or by other means. After denaturation, the oil can be extracted by an optional selection of nonpolar and polar solvents including use of supercritical carbon dioxide. Krill is adapted to a very efficient nutrient digestion at very low temperatures. Therefore the enzymes are sensitive to heat and the step of applying thermal denaturation of lipases and phospholipases does not imply use of very high temperatures. Surprisingly, it has been found that the use of mild denaturation conditions can greatly enhance the quality of krill oil. Additionally, a major obstacle of several processes of extraction is the cost of removing water. This is particularly true for methods feasible for extraction of highly unsaturated lipids where freeze drying has been regarded as the method of choice to avoid oxidative breakdown of lipids. However, the lipids in krill are surprisingly stable against oxidative deterioration. Therefore, a process including moderate use of heat in the water removing process is feasible provided that the enzymes have been inactivated.

A. Krill Processing The present invention provides methods for processing freshly caught krill at the site of capture and preferably on board a ship. After processing on board, the krill can be further subjected to extraction processes on board the ship or at a remote location away from the ship. The processing steps described herein also allow for the storage of krill material, preferably a krill meal for from about 1,2, 3, 4, 5, 6, 8, 9, 10, 11, or 12 months to about 24 to 36 months prior to processing.

In some preferred embodiments, freshly caught krill is first subjected to a protein denaturation step. The present invention is not limited to any particular method of protein denaturation. In some embodiments, the denaturation is accomplished by application of chemicals, heat, or combinations thereof. In some embodiments, freshly caught krill is wet pressed to obtain oil and meal. In some embodiments, the meal is then heated to a temperature of about 500C to about 100°C for about 20 minutes to about an hour, preferably about 40 minutes to denature the proteins. In some embodiments, this material is then pressed to yield a press cake. When this method is used on krill, only a small amount of oil is released. Most of the oil is still present in the denatured meal. In some embodiments, antioxidants such as ethoxyquin or Vitamin E are added to the meal. However, as shown in the examples, the resulting meal is surprisingly stable. The stability can only partly be explained by addition of an antioxidant to the meal. This antioxidant can, after extraction of the oil from denatured meal, be removed by further processing steps. Alternatively the oil can be extracted rather shortly after production of the meal without any addition of antioxidant in the process. Further, storage conditions at a low to very low temperature can be applied if addition of antioxidant is not desired.

Krill oil extracted from denatured krill meal by supercritical fluid extraction even 19 months after the production of the meal contained virtually no decomposed phospholipids. This product turned out to be substantially different from samples of krill oil available in the market today. Previously described commercial krill processing procedures utilize krill that has been frozen immediately after catching followed by freeze drying and extraction at low temperatures. However, these processes only yield a suitable product if the time the krill is kept frozen is very short or the temperature is extremely low (-60°to -80°C). However, data provided herein clearly shows that if a step of denaturation of the proteins is added in front of an optional extraction method, an excellent krill oil can be produced even after a long time of storage. This methodology also opens up for use of alternative methods to remove water prior to extraction, which in turn has a great impact on costs in full scale operation. If a long time of storage is desired, the denatured material should preferably be stored at low temperature preferably at -2O0C.

In some embodiments, krill oil is extracted from the denatured krill meal. In some embodiments, the krill oil is extracted by contacting the krill meal with ethanol. In some embodiments, krill is then extracted with a ketone solvent such as acetone. In other embodiments, the krill oil is extracted by one or two step supercritical fluid extraction. In some embodiments, the supercritical fluid extraction uses carbon dioxide and neutral krill oil is produced. In some embodiments, the supercritical fluid extraction uses carbon dioxide with the addition of a polar entrainer, such as ethanol, to produce a polar krill oil. In some embodiments, the krill meal is first extracted with carbon dioxide followed by carbon dioxide with a polar entrainer, or vice versa. In some embodiments, the krill meal is first extracted with CO2 supplemented with a low amount of a polar co-solvent (e.g., from about 1 % to about 10%, preferably about 5%) such a C1-C3 monohydric alcohol, preferably ethanol, followed by extraction with CO2 supplemented with a high amount of a polar co-solvent (from about 10% to about 30%, preferably about 23%) such as such a C1-C3 monohydric alcohol, preferably ethanol, or vice versa. Surprisingly, it has been found that use of a low amount of polar solvent in the CO2 as an entrainer facilitates the extraction of neutral lipid components and astaxanthin in a single step. Use of the high of polar solvent as an entrainer in the other step facilitates extraction of ether phospholipids, as well as non-ether phospholipids.

The present invention is distinguished from previously described krill oil products, such as those described in U.S. Pat. No. 6,800,299 or WO 03/011873 and Neptune brand krill oil, by having substantially higher levels of non-ether phospholipids, ether phospholipids, and astaxanthin. The krill oils of the present invention also have, unexpected and superior properties as compared to previously available krill oils. In particular, the krill oil of the present invention has been demonstrated to reduce blood LDL cholesterol levels, improve DHA transfer to the brain as well as reduce lipid accumulation in the liver and muscle while the previously described krill oil compositions do not have such a properties. Accordingly, in some embodiments, the present invention provides a krill oil composition, preferably a

Euphausia superba krill oil composition, comprising from about 40% to about 60% w/w phospholipids, preferably from about 45% to 55% w/w phospholipids and from about 300 mg/kg astaxanthin to about 2500 mg/kg astaxanthin, preferably from about 1000 to about 2200 mg/kg astaxanthin, more preferably from about 1500 to about 2200 mg/kg astaxanthin. In some preferred embodiments, the compositions comprise greater than about 1000, 1500, 1800, 1900, 2000, or 2100 mg/kg astaxanthin. In some preferred embodiments, the krill oil compositions of the present invention comprise from about 1%, 2%, 3% or 4% to about 8%, 10%, 12% or 15% w/w ether phospholipids or greater than about 4%, 5%, 6%, 7%, 8%, 9% or 10% ether phospholipids. In some embodiments the ether phospholipids are preferably alkylacylphosphatidylcholine, lyso-alkylacylphosphatidylcholine, alkylacylphosphatidyl- ethanolamine or combinations thereof. In some embodiments, the krill oil compositions comprise from about 1%, 2%, 3% or 4% to about 8%, 10%, 12% or 15% w/w ether phospholipids and from about 30%, 33%, 40%, 42%, 45%, 48%, 50%, 52%, 54%, 55% 56%, 58% to about 60% non-ether phospholipids so that the total amount of phospholipids (both ether and non-ether phospholipids) ranges from about 40% to about 60%. One of skill in the art will recognize that the range of 40% to 60% total phospholipids, as well as the other ranges of ether and non-ether phospholipids, can include other values not specifically listed within the range.

In further embodiments, the compositions comprise from about 20% to 45% w/w triglycerides; and from about 400 to about 2500 mg/kg astaxanthin. In some embodiments, the compositions comprise from about 20% to 35%, preferably from about 25% to 35%, omega-3 fatty acids as a percentage of total fatty acids in the composition, wherein from about 70% to 95%, or preferably from about 80% to 90% of the omega-3 fatty acids are attached to the phospholipids. In some embodiments, the present invention provides encapsulated Euphausia superba krill oil compositions. In some embodiments, the present invention provides a method of making a Euphausia superba krill oil composition comprising contacting Euphausia superba with a polar solvent to provide an polar extract comprising phospholipids, contacting Euphausia superba with a neutral solvent to provide a neutral extract comprising triglycerides and astaxanthin, and combining said polar extract and said neutral extract to provide the Euphausia superba krill oils described above. In some embodiments, fractions from polar and non-polar extractions are combined to provide a final product comprising the desired ether phospholipids, non-ether phospholipids, omega-3 moieties and astaxanthin. In other embodiments, the present invention provides methods of making a Euphausia superba (or other krill species) krill oil comprising contacting a Euphausia superba preparation such as Euphausia superba krill meal under supercritical conditions with CO2 containing a low amount of a polar solvent such as ethanol to extract neutral lipids and astaxanthin; contacting meal remaining from the first extraction step under supercritical conditions with CO2 containing a high amount of a polar solvent such as ethanol to extract a polar lipid fraction containing ether and non-ether phospholipids; and then blending the neutral and polar lipid extracts to provide the compositions described above.

The krill oil extracted by the methods of the present invention contains few enzymatic breakdown products. Examples of the krill oil compositions of the present invention are provided in Tables 9-24. In some embodiments, the present invention provides a polar krill oil comprising at least 65% (w/w) of phospholipids, wherein the phospholipids are characterized in containing at least 35% omega-3 fatty acid residues. The present invention is not limited to the presence of any particular omega-3 fatty acid residues in the krill oil composition. In some preferred embodiments, the krill oil comprises EPA and DHA residues.

In some embodiments, the krill oil compositions comprise less than about 5%, 4%, 3% or preferably 2% free fatty acids on a weight/weight (w/w) basis. In some embodiments, the krill oil compositions comprise less than about 25%, 20%, 15%, 10% or 5% triglycerides

(w/w). In some embodiments, the krill oil compositions comprise greater than about 30%, 40%, 45%, 50%, 55%, 60%, or 65% phosphatidyl choline (w/w). In some embodiments, the krill oil compositions comprise greater than about 100, 200, 300, 400, or 500 mg/kg astaxanthin esters and up to about 700 mg/kg astaxanthin esters. In some embodiments, the present invention provides krill oil compositions comprising at least 500, 1000, 1500, 2000, 2100, or 2200 mg/kg astaxanthin esters and at least 36% (w/w) omega-3 fatty acids. In some embodiments, the krill oil compositions of the present invention comprise less than about l.Og/lOOg, 0.5g/100g, 0.2g/100g or O.lg/lOOg total cholesterol. In some embodiments, the krill oil compositions of the present invention comprise less than about .0.45

In some embodiments, the present invention provides a neutral krill oil extract comprising greater than about 70%, 75% 80%, 85% or 90% triglycerides. In some embodiments, the krill oil compositions comprise from about 50 to about 2500 mg/kg astaxanthin esters. In some embodiments, the krill oil compositions comprise from about 50, 100, 200, or 500 to about 750, 1000, 1500 or 2500 mg/kg astaxanthin esters. In some embodiments, the compositions comprise from about 1% to about 30% omega-3 fatty acid residues, and preferably from about 5%-15% omega-3 fatty acid residues. In some embodiments, the krill oil compositions comprise less than about 20%, 15%, 10% or 5% phospholipids.

In some embodiments, the present invention provides krill oil containing less than about 70, 60, 50, 40, 30, 20, 10, 5 or 1 micrograms/kilogram (w/w) astaxanthin esters. In some embodiments, the krill oil is clear or only has a pale red color. In some embodiments, the low-astaxanthin krill oil is obtained by first extracting a krill material, such as krill oil, by supercritical fluid extraction with neat carbon dioxide. It is contemplated that this step removes astaxanthin from the krill material, hi some embodiments, the krill material is then subjected to supercritical fluid extraction with carbon dioxide and a polar entrainer such as ethanol, preferably about 20% ethanol. The oil extracted during this step is characterized in containing low amounts of astaxanthin. In other embodiments, krill oil comprising astaxanthin is extracted by countercurrent supercritical fluid extraction with neat carbon dioxide to provide a low-astaxanthin krill oil.

In some embodiments, the present invention provides krill oil that is substantially odorless. By substantially odorless it is meant that the krill oil lacks an appreciable odor as determined by a test panel. In some embodiments, the substantially odorless krill oil comprises less than about 10, 5 or 1 milligrams/kilogram trimethylamine. In some preferred embodiments, the odorless krill oil is produced by first subjecting krill material to supercritical fluid extraction with neat carbon dioxide to remove odor causing compounds such as trimethylamine, followed by extraction with carbon dioxide with a polar entrainer such as ethanol.

In some embodiments, the present invention provides a delipidated krill meal produced after extraction of lipids from the krill meal. In some embodiments, the delipidated krill meal comprises krill protein. In some embodiments, the delipidated krill meal comprises less than about 200, 150, 120, 100, 75, 65, 60, 55, or 50 g/kg total fat. In some embodiments, the delipidated krill meal comprises from about 1 to about 100 mg/kg astaxanthin esters, and preferably from about 5 to about 20 mg/kg astaxanthin esters. In some embodiments, the delipidated krill meal comprises greater than about 60%, 65%, 70% or 75% krill protein. In some embodiments, the present invention provides animal feeds comprising the delipidated krill meal. In some embodiments, the animal feed is a fish feed or aquatic organism feed, such as shrimp feed, crab feed, or crawfish feed. In preferred embodiments, the krill meal is incorporated into complete ration for the target organism. In preferred embodiments, the feed is provided in pelleted form. In many instances, compounds such as astaxanthin are removed during delipidation. The methods of the present invention provide a delipidated krill meal that retains significant amounts of astaxanthin. Accordingly, in some embodiments, the present invention provides methods of feeding aquatic organisms, comprising providing to the aquatic organism a feed comprising the delipidated krill meal described above. In other embodiments, the present invention provides methods of increasing flesh coloration in an aquatic species comprising feeding the aquatic species a comprising the delipidated krill meal described above.

B. Compositions Containing Krill Oil In some embodiments, the compositions of this invention (such as those described in the preceding sections) are contained in acceptable excipients and/or carriers for oral consumption. The actual form of the carrier, and thus, the composition itself, is not critical.

The carrier may be a liquid, gel, gelcap, capsule, powder, solid tablet (coated or non-coated),

- —tea, or the like. . The composition is. preferably in the form of a .tablet or capsule and most preferably in the form of a soft gel capsule. Suitable excipient and/or carriers include maltodextrin, calcium carbonate, dicalcium phosphate, tricalcium phosphate, macrocrystalline . cellulose, dextrose, rice flour, magnesium stearate, stearic acid, croscarmellose sodium, sodium starch glycolate, crospovidone, sucrose, vegetable gums, lactose, methylcellulose, povidone, carboxymethylcellulose, corn starch, and the like (including mixtures thereof). Preferred carriers include calcium carbonate, magnesium stearate, maltodextrin, and mixtures thereof. The various ingredients and the excipient and/or carrier are mixed and formed into the desired form using conventional techniques. The tablet or capsule of the present invention may be coated with an enteric coating that dissolves at a pH of about 6.0 to 7.0. A suitable enteric coating that dissolves in the small intestine but not in the stomach is cellulose acetate phthalate. Further details on techniques for formulation for and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

The dietary supplement may comprise one or more inert ingredients, especially if it is desirable to limit the number of calories added to the diet by the dietary supplement. For example, the dietary supplement of the present invention may also contain optional ingredients including, for example, herbs, vitamins, minerals, enhancers, colorants, sweeteners, flavorants, inert ingredients, and the like. For example, the dietary supplement of the present invention may contain one or more of the following: ascorbates (ascorbic acid, mineral ascorbate salts, rose hips, acerola, and the like), dehydroepiandosterone (DHEA), Fo- Ti or Ho Shu Wu (herb common to traditional Asian treatments), Cat's Claw (ancient herbal ingredient), green tea (polyphenols), inositol, kelp, dulse, bioflavinoids, maltodextrin, nettles, niacin, niacinamide, rosemary, selenium, silica (silicon dioxide, silica gel, horsetail, shavegrass, and the like), spirulina, zinc, and the like. Such optional ingredients may be either naturally occurring or concentrated forms. In some embodiments, the dietary supplements further comprise vitamins and minerals including, but not limited to, calcium phosphate or acetate, tribasic; potassium phosphate, dibasic; magnesium sulfate or oxide; salt (sodium chloride); potassium chloride or acetate; ascorbic acid; ferric orthophosphate; niacinamide; zinc sulfate or oxide; calcium pantothenate; copper gluconate; riboflavin; beta-carotene; pyridoxine hydrochloride; thiamin mononitrate; folic acid; biotin; chromium chloride or picolonate; potassium iodide; sodium selenate; sodium molybdate; phylloquinone; vitamin D3; cyanocobalamin; sodium selenite; copper sulfate; vitamin A; vitamin C; inositol; potassium iodide. Suitable dosages for vitamins and minerals may be obtained, for example, by consulting the U.S. RDA guidelines. In further embodiments, the compositions comprise at least one food flavoring such as acetaldehyde (ethanal), acetoin (acetyl methylcarbinol), anethole (parapropenyl anisole), benzaldehyde (benzoic aldehyde), N butyric acid (butanoic acid), d or 1 carvone (carvol), cinnamaldehyde (cinnamic aldehyde), citral (2,6 dimethyloctadien 2,6 al 8, gera nial, neral), decanal (N decylaldehyde, capraldehyde, capric aldehyde, caprinaldehyde, aldehyde C 10), ethyl acetate, ethyl butyrate, 3 methyl 3 phenyl glycidic acid ethyl ester (ethyl methyl phenyl glycidate, strawberry aldehyde, C 16 aldehyde), ethyl vanillin, geraniol (3,7 dimethyl 2,6 and

3.6 octadien 1 ol), geranyl acetate (geraniol acetate), limonene (d , 1 , and dl ), linalool (linalol,

3.7 dimethyl 1,6 octadien 3 ol), linalyl acetate (bergamol), methyl anthranilate (methyl 2 aminobenzoate), piperonal (3,4 methylenedioxy benzaldehyde, heliotropin), vanillin, alfalfa (Medicago sativa L.), allspice (Pimenta officinalis), ambrette seed (Hibiscus abelmoschusj, angelic (Angelica archangelica), Angostura (Galipea officinalis), anise (Pimpinella anisum), star anise (Illicium verum), balm (Melissa officinalis), basil (Ocimum basilicum), bay (Laurus nobilis), calendula (Calendula officinalis), (Anthemis nobilis), capsicum (Capsicum frutescens), caraway (Carum carvi), cardamom (Elettaria cardamomum), cassia, (Cinnamomum cassia), cayenne pepper (Capsicum frutescens), Celery seed (Apium graveolens), chervil (Anthriscus cerefolium), chives (Allium schoenoprasum), coriander (Coriandrum sativum), cumin (Cuminum cyminum), elder flowers (Sambucus canadensis), fennel (Foeniculum vulgare), fenugreek (Trigonella foenum graecum), ginger (Zingiber officinale), horehound (Marrubium vulgare), horseradish (Armoracia lapathifolia), hyssop (Hyssopus officinalis), lavender (Lavandula officinalis), mace (Myristica fragrans), marjoram (Majorana hortensis), mustard (Brassica nigra, Brassica juncea, Brassica hirta), nutmeg (Myristica fragrans), paprika (Capsicum annuum), black pepper (Piper nigrum), peppermint (Mentha piperita), poppy seed (Papayer somniferum), rosemary (Rosmarinus officinalis), saffron (Crocus sativus), sage (Salvia officinalis), savory (Satureia hortensis, Satureia montana), sesame (Sesamum indicum), spearmint (Mentha spicata), tarragon (Artemisia dracunculus), thyme (Thymus vulgaris, Thymus . serpyllum), turmeric (Curcuma longa), vanilla (Vanilla planifolia), zedoary (Curcuma zedoaria), sucrose, glucose, saccharin, sorbitol, mannitol, aspartame. Other suitable flavoring are disclosed in such references as Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing, p. 1288-1300 (1990), and Furia and Pellanca, Fenaroli's Handbook of Flavor Ingredients, The Chemical Rubber Company, Cleveland, Ohio, (1971), known to those skilled in the art.

In other embodiments, the compositions comprise at least one synthetic or natural food coloring (e.g., annatto extract, astaxanthin, beet powder, ultramarine blue, canthaxanthin, caramel, carotenal, beta carotene, carmine, toasted cottonseed flour, ferrous gluconate, ferrous lactate, grape color extract, grape skin extract, iron oxide, fruit juice, vegetable juice, dried algae meal, tagetes meal, carrot oil, corn endosperm oil, paprika, paprika oleoresin, riboflavin, saffron, tumeric, tumeric and oleoresin).

In still further embodiments, the compositions comprise at least one phytonutrient (e.g., soy isoflavonoids, oligomeric proanthcyanidins, indol 3 carbinol, sulforaphone, fibrous ligands, plant phytosterols, ferulic acid, anthocyanocides, triterpenes, omega 3/6 fatty acids, conjugated fatty acids such as conjugated linoleic acid and conjugated linolenic acid, polyacetylene, quinones, terpenes, cathechins, gallates, and quercitin). Sources of plant phytonutrients include, but are not limited to, soy lecithin, soy isoflavones, brown rice germ, royal jelly, bee propolis, acerola berry juice powder, Japanese green tea, grape seed extract, grape skin extract, carrot juice, bilberry, flaxseed meal, bee pollen, ginkgo biloba, primrose (evening primrose oil), red clover, burdock root, dandelion, parsley, rose hips, milk thistle, ginger, Siberian ginseng, rosemary, curcumin, garlic, lycopene, grapefruit seed extract, spinach, and broccoli. In still other embodiments, the compositions comprise at least one vitamin (e.g., vitamin A, thiamin (Bl), riboflavin (B2), pyridoxine (B6), cyanocobalamin (B 12), biotin, ascorbic acid (vitamin C), retinoic acid (vitamin D), vitamin E, folic acid and other folates, vitamin K, niacin, and pantothenic acid). In some embodiments, the particles comprise at least one mineral (e.g., sodium, potassium, magnesium, calcium, phosphorus, chlorine, iron, zinc, manganese, flourine, copper, molybdenum, chromium, selenium, and iodine). In some particularly preferred embodiments, a dosage of a plurality of particles includes vitamins or minerals in the range of the recommended daily allowance (RDA) as specified by the United States Department of Agriculture. In still other embodiments, the particles comprise an amino acid supplement formula in which at least one amino acid is included (e.g., 1-carnitine or tryptophan).

C. Uses of KrilI Oil Previously, it was disclosed that omega-3 fatty acids have anti-inflammatory properties. See, e.g., Calder. Am. J. Clin. Nutr. 83 (2006) 1505S. In addition, in it was disclosed that a phospholipid emulsion derived from a marine and/or synthetic origin comprising polyunsaturated fatty acids have anti-inflammatory and/or immuno-suppressive effects. See, e.g., 5,434,183. An embodiment of this invention is a krill oil composition effective for reducing inflammation i.e. reducing the levels of TNF-α, IL-I beta, IL-6, IL-10, TGF beta and fibrinogen in the blood.

Type 2 diabetes is a metabolic disorder characterized by impaired glycemic control (high blood glucose levels). In type 2 diabetes, it is the tissue wide insulin resistance that contributes to the development of the disease. Strategies reducing insulin resistance or improving tissue sensitivity to insulin are recognized as beneficial in preventing type 2 diabetes. In healthy humans, a 3-week supplementation with fish oil (1.1 g EPA/d and 0.7 g DHA/d) decreased the insulin response to an oral glucose load by 40%. Omega-3 PUFA dietary enrichment resulted in lower glucose oxidation, higher fat oxidation, and increased glycogen storage; the glycemic response was unchanged, however, which indicates an improved sensitivity to insulin, hi another embodiment of this invention is a krill oil composition effective for reducing the insulin resistance.

Krill oil has not been disclosed as being effective in treating one of the most important life style problems of modern societies, i.e., excess weight gain and obesity. Excess adipose tissue mass (overweight and obesity) is associated with low grade inflammation in adipose tissue and in the whole body reflecting the inflammatory mediators "spilling over" from fat tissue. Trayhurn et al., Br. J. Nutrition (2004), 92(3), 347-355. Inflammation appears to be an important link between obesity and metabolic syndrome/type-II diabetes as well as cardiovascular disease. Libby et al., J. Amer. Coll. Card. (2006), 48(9, Suppl, A), A33-A46. Thus, excess adipose tissue is an unhealthy condition. Weight reduction will improve the inflammatory condition, but persistent weight reduction is difficult to achieve. Omega-3 fatty acid supplementation may alleviate the inflammatory condition in adipose tissue and thus ideally complement the principal strategies of weight reduction i.e. low calorie diet and exercise. There are clinical studies in humans that demonstrate that omega-3 enhance the effect of very low calorie diet and exercise in reducing body fat mass. Kunesova et al., Physiological research / Academia Scientiarum Bohemoslovaca (2006), 55(1), 63-72. Although diet and exercise regime may fail to result in consistent decrease in weight in long term, the effect of omega-3 fatty acids alleviating the inflammatory condition in the adipose tissue may persist generating a condition that can be described as "healthy adipose tissue". Previously, it was shown that dietary omega-3 fatty acids can be used to reduce inflammation in adipose tissue without influencing level of obesity. Todoric et al., Diabetologia (2006), 49(9), 2109-2119. Reduction in adipose tissue inflammation was demonstrated by an increase in circulating levels of adiponectin. Adiponectin is an adipose tissue derived antiinflammatory hormone. Results on the treatment of obese people with omega-3 fatty acids to alleviate circulating levels of inflammatory markers are inconclusive. Trebble et al., Br. J. Nutrition (2003), 90(2), 405-412. However, duration of these studies may not have been sufficient given the slow turnover of adipose tissue in humans. Itoh et al. found that 1.8 g/d of EPA increased adiponectin, a marker of adipose tissue derived inflammation, in a group of overweight subjects with metabolic syndrome. Itoh et al., Arteriosclerosis, Thrombosis, and Vascular Biology (2007), 27(9), 1918-1925.

An embodiment of the invention is the use of krill oil to increase serum adiponectin levels. Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism. Adiponectin is exclusively secreted from adipose tissue into the bloodstream and is very abundant in plasma relative to many hormones. Levels of the hormone are inversely correlated with body mass index (BMI). The hormone plays a role in alleviating the metabolic dysregulation that may result in type 2 diabetes, obesity, atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Diez et al., Eur. J. Endocrinol. 148 (3): 293-300; Ukkola et al., J. MoI. Med. 80 (11): 696-702.

Another embodiment of the invention is to use krill oil in an overweight and obese subjects for alleviating diet induced adipose tissue dysfunction and diet induced changes in the lipid metabolism.

In further embodiments, krill oil is effective in reducing risk factors of type 2 diabetes such as hyperinsulinemia and insulin resistance and cardiovascular disease risk factors in overweight subjects. In addition this invention discloses that krill oil is effective in preventing accumulation of fat in muscles and in the liver (liver steatosis).

It is well known in the art that the obese Zucker rat is a useful rat model to study metabolic Syndrome X and non-insulin dependent diabetes mellitus, including glucose tolerance, insulin resistance and hyperinsulinaemia. It has also been shown previously that astaxanthin is a powerful antioxidant, useful for prevention of oxidative stress in vivo and in Zucker rats using vitamin E. See, e.g., Aoi et al., (2003). Antioxidants & Redox Signaling. 5(l):139-44; Laight et al., Eur. J. Pharmacol. 377 (1999) 89.

In yet another embodiment of the invention is a krill oil composition effective of improving the blood lipid profile by increasing the HDL cholesterol levels, decreasing the LDL cholesterol and triglyceride levels. Hence the novel krill oil composition is effective for treating metabolic syndrome. Metabolic syndrome is defined as the coexistence of 3 or more components selected from the group: abdominal obesity, high serum triglyceride levels, low HDL levels, elevated blood pressure and high fasting plasma glucose levels.

In another embodiment of the invention, the krill oil compositions are found to be effective and safe for the treatment of metabolic syndrome in humans.

In still other embodiments, the krill oil compositions of the present invention find use in increasing or inducing diuresis. In some embodiments, the krill oil compositions of the present invention find use in decreasing protein catabolism and increasing the muscle mass of a subject. In some embodiments, the kill oil composition of the present invention find use in the treatment of fatty heart disease and non-alcoholic fatty acid liver disease. Thus, the krill oil compositions are useful for decreasing the lipid content of the heart and/or liver and/or muscle of a subject.

In yet another embodiment of the invention is a method to increase the transfer of DHA to the brain.

EXAMPLE 1

Antarctic krill {Euphausia superbd) was captured and brought on board alive, before it was processed into krill meal, an oil (asta oil) and stickwater. The composition and properties of the krill meal was monitored during the processing and compared to a commercial competitor (Table 1 and 2). Furthermore, the amino acid composition of the krill meal and stickwater was determined (Table 3), showing that krill meal is a suitable feed source for to be used in aquaculture due to the presences of all the essential amino acids teleost fish require. During the krill meal processing a neutral oil (asta oil) is recovered, the chemical composition of the asta oil is shown in Tables 4 and 5.

Table 1. Com osition of roducts from the rocessin line

Nd= not detected Table 3. Amino acids in krill meal and stick water

3-aminopropanoic acid is also known as β-alanine

4-aminobutanoic acid is alos known as γ-aminobutyric acid or GABA

Table 4. Composition and ualit arameters of asta oil.

Table 5. Fatty acid composition of the asta oil

EXAMPLE 2 The krill meal obtained in example 1 was then ethanol extracted according to the method disclosed in JP02215351. The results showed that around 22% fat from the meal could be extracted, somewhat lower than was extracted using Folch (25%). Table 6 shows the fatty acid composition of the krill meal and the krill oil extracted from the meal using ethanol. Table 7 shows the composition and properties of the krill meal and products before and after extraction, whereas table 8 shows the lipid composition.

Table 6 krill meal (g/100 g lipid) and the ethanol extracted krill oil. O

Saturated 24,6 21,9 Monouns atur ated 19,9 17,0 Polyunsaturated 21,0 19,4

Total 65,5 58,2

Omega-3 18,2 17,0 Omega-6 1,3

Table 7. Composition and properties of the krill meal and products after extraction

EXAMPLE 3

The krill meal obtained in example 1 was then subjected to a supercritical fluid extraction method in two stages. During stage 1, 12.1% fat (neutral krill oil) was removed using neat CO2 only at 300 bars, 60° C and for 30 minutes, hi stage 2, the pressure was increased to 400 bar and 20% ethanol was added (v/v) for 90 minutes. This resulted in further extraction of 9% polar fat which hereafter is called polar krill oil. The total fatty acid composition of the polar krill oil, the neutral krill oil and a commercial product obtained from Neptune Biotech (Laval, Quebec, Canada) are listed in Table 9. hi addition the fatty acid composition for the phospholipids (Table 10), the neutral lipids (Table 11), the free fatty acids, diglycerides (Table 12), triglycerides, lyso-phosphatidylcholine (LPC) (Table 13), phosphatidylcholine (PC), phosphatidylethanolamine (PE) (Table 14), phosphatidylinositol (PI) and phosphatidylserine (PS) (Table 15) are shown. Table 16 shows the level of astaxanthin and cholesterol for the different fractions.

Table 9. Total fatty acids compositions of the krill oil products (% (w/w))

Total Fatty Acids

Neutral Polar

Fatty Acid NKO KO KO

File

C4:0 0,00 0,00 0,00

C6:0 0,00 0,00 0,00

C8:0 0,00 0,00 0,00

C10:0 O5OO 0,00 0,00

C12:0 0,47 0,04 0,24

C14:0 22,08 3,28 12,48

C14:l 0,33 0,01 0,17

C15:0 0,58 0,36 0,52

C16:0 27,03 29,25 23,25

C16:l 0,07 0,01 8,44

C18:0 1,72 1,03 1,42

C18:l 30,29 13,57 18,92

C18:2N6 2,10 1,96 1,71

C18:3N6 0,30 0,21 0,00

C18:3N3 0,69 1,02 1,32

C18:4N3 0,05 1,81 3,50 ,

Table 10. Fatty acid composition of the phospholipid fraction (% (w/w)).

Total Phospholipid

Neutral Polar Neptune

Fatty Acid

KO KO KO

File

C4:0 0,00 0,00 0,00

C6:0 0,00 0,00 0,00

C8:0 0,00 0,00 0,00

C10:0 0,00 0,00 0,00

C12:0 0,00 0,00 0,00

C14:0 0,01 0,00 0,00

C14.1 0,42 0,01 0,01

C15:0 2,52 0,00 0,00

C16:0 4,73 35,78 32,81

C16:l 0,19 0,17 0,19

C18:0 6,31 1,18 1,55

C18:l 38,40 15,58 .13,54

C18:2N6 4,18 2,16 1,90

C18.-3N6 0,18 0,22 0,19

C18:3N3 1,02 1,05 1,48

Table 11. Fatty acid composition of the total neutral lipid fraction (% (w/w)). e

Table 12. Fatty acid composition of the diglyceride and free fatty acids (% (w/w)).

Diglycerides Free fatty acids feutral Polar Neptune Neutral Neptune

Fatty. Acid Polar KO

KO KO KO KO KO

File

C4:0 0,00 0,00 0,00 0,00 0,00 0,00

C6:0 0,00 0,00 0,00 0,00 0,00 0,00

C8:0 0,00 0,00 0,00 0,00 0,00 0,00

C10:0 0,00 0,00 0,00 0,00 0,00 0,00

C12:0 0,00 0,00 0,00 0,00 0,00 0,00

C14:0 13,85 14,35 12,22 5,86 7,19 5,45

C14:l 0,18 0,00 0,17 0,05 0,00 0,08

C15:0 0,49 1,08 0,66 0,46 1,60 0,45

C16:0 23,68 35,24 25,81 28,30 29,37 21,12

C16:l 9,49 6,80 0,09 3,27 3,08 4,91

C18:0 1,56 3,63 1,89 1,13 2,43 . 0,99 C18:l 23,67 19,85 23,82 14,50 14,77 17,41 C18:2N6 1,79 0,21 1,90 1,69 0,97 1,86 C18:3N6 0,17 0,00 0,01 0,14 0,00 0,22 C18:3N3 0,69 0,00 1,19 0,85 0,00 1,34 C18:4N3 1,92 0,00 2,75 1,30 0,00 2,72 .

C20:0 0,00 0,00 0,00 0,00 0,00 0,00

C20:l 1,09 0,00 1,01 0,48 0,00 0,57 C20:2N6 0,00 0,00 0,00 0,00 0,00 0,00 C20:3N6 0,13 0,00 0,00 0,08 0,00 0,05 C20:4N6 0,45 0,00 0,64 0,78 0,00 1,43 C20:3N3 0,00 0,00 0,00 0,00 0,00 0,00 C20:4N3 0,35 0,00 0,43 . 0,39 0,00 0,43 C20:5N3 (EPA) 14,03 .9,80 18,00 24,33 23,57 25,36

C22:0 0,18 0,00 0,10 0,00 0,00 0,05

C22:l 0,41 0,00 0,57 0,80 0,69 0,37

' C22:2N6 0,28 0,00 0,50 0,46 0,00 0,54

C22:4N6 0,00 0,00 0,00 0,00 0,00 0,00

C22:5N6 0,00 0,00 O3OO 0,00 0,00 0,00

C22:5N3 0,20 0,00 0,27 0,34 0,00 0,32

C22:6N3 (DHA) 4,74 9,04 7,53 14,31 16,33 13,95

C24:0 0,64 0,00 0,42 0,49 0,00 0,39

C24:l 0,00 0,00 0,00 0,00 0,00 0,00

Total 100,00 100,00 100,00 100,00 100,00 100,00

Saturated 40,40 54,30 41,10 36,24 40,59 28,45

Monounsaturated 34,84 26,64 25,66 19,09 18,54 23,34

Polyunsaturated 24,77 19,06 33,24 44,67 40,87 48,22

Total 100,00 100,00 100,00 100,00 100,00 100,00

Omega-3 21,95 18,85 30,18 41,51 39,90 44,13 Omega-6 2,82 0,21 3,05 3,15 0,97 4,09

Table 13. Fatty acid composition of the triglyceride and lyso-phophatidylcholine fractions (% (w/w)).

Triglycerides Lyso PC

Neutral Polar Neptune Neutral Polar Neptune tty Acid

KO KO KO KO KO KO

File

C4:0 0,00 0,00 0,00 0,00 0,00 0,00

C6:0 0,00 0,00 0,00 0,00 0,00 0,00

C8:0 0,00 0,00 0,00 0,00 0,00 0,00

ClOrO 0,00 0,00 0,00 0,00 0,00 0,00

C12:0 0,00 0,00 0,00 0,00 0,00 0,00

C14:0 23,06 26,65 25,13 19,38 4,27 2,87

C14:l 0,36 0,93 0,36 0,00 0,08 0,00' C15:0 0,56 2,64 0,78 0,00 0,52 0,45

C16:0 23,17 4,93 27,80 41,00 44,14 30,56

C16:l 13,68 11,58 0,04 0,00 1,84 2,24

C18:0 1,52 3,12 1,99 0,76 1,59 1,32

C18:l 27,83 34,39 27,92 6,65 14,24 11,29 C18:2N6 1,64 2,05 1,92 0,00 1,75 2,07 C18:3N6 0,20 0,00 0,30 0,00 0,00 0,06 C18:3N3 0,51 0,00 0,00 7,95 0,67 1,75 C18:4N3 1,99 0,00 4,83 0,00 1,11 2,46

C20:0 0,06 0,00 0,08 0,00 0,00 0,00

C20:l 1,67 0,00 1,76 0,00 0,52 0,00 C20:2N6 0,04 0,00 0,05 0,00 0,00 0,00 C20:3N6 0,05 0,00 0,01 0,00 0,00 0,54 C20:4N6 0,00 0,00 0,00 0,00 0,40 0,00 C20:3N3 0,05 0,00 0,07 0,00 0,00 0,00 C20:4N3 0,11 O5OO 0,17 0,00 0,31 0,55 C20:5N3 (EPA) 2,10 7,97 4,44 0,00 18,59 28,48

C22:0 0,02 0,00 0,04 0,00 0,00 0,00

C22:l 0,37 0,00 0,42 0,00 1,46 0,91 C22:2N6 0,00 0,00 0,00 0,00 0,00 0,00 C22:4N6 0,01 0,00 0,01 0,00 0,00 0,00 C22:5N6 0,00 0,00 0,01 0,00 0,00 0,00 C22:5N3 0,10 0,00 0,16 0,00 0,41 0,62 C22:6N3 (DHA) 0,67 3,97 1,42 24,26 7,79 13,82

C24:0 0,26 1,78 0,26 0,00 0,32 0,00

C24:l 0,00 0,00 0,03 0,00 0,00 0,00

Total 100,00 100,00 100,00 100,00 100,00 100,00

Saturated 48,64 39,12 56,08 61,14 50,83 35,21

Monouns atur ated 43,90 46,89 30,52 6,65 18,14 14,44

Polyunsaturated 7,45 13,99 13,41 32,20 31,02 50,35

Total 100,00 100,00 100,00 100,00 100,00 100,00

Omega-3 5,51 11,94 11,11 32,20 28,87 47,69 Omega-6 1,94 2,05 2,30 0,00 2,15 2,66

Table 14. Fatty acid composition of the phosphatidylcholine and the phosphatidylserine fractions (% (w/w)).

PC PS

Neutral Polar Neptune Neutral Polar Neptune

Fatty Acid KO KO KO KO KO KO

File C4:0 0,00 0,00 0,00 0,00 0,00 0,00 C6:0 0,00 0,00 0,00 0,00 0,00 0,00 C8:0 0,00 0,00 0,00 0,00 0,00 0,00 C10:0 0,00 0,00 0,00 0,00 0,00 0,00

C12:0 0,00 0,00 0,00 0,00 0,00 0,00

C14:0 0,75 3,29 2,77 7,60 9,52 2,31

C14-.1 2,07 0,04 0,02 0,00 0,00 0,00

C15:0 1,34 0,00 0,00 3,83 0,00 0,00

C16:0 16,65 31,92 29,83 30,44 43,61 19,49

C16:l 0,96 0,01 0,17 9,96 3,47 2,79

C18:0 1,33 1,06 1,33 2,08 3,34 2,24

C18:l 34,34 13,55 11,16 0,00 7,37 11,87 C18:2N6 10,55 2,27 1,90 0,00 0,00 0,00 C18:3N6 1,44 0,25 0,20 0,00 0,00 0,00 C18:3N3 2,49 1,19 1,54 0,00 0,00 O5OO C18:4N3 2,38 1,92 2,41 0,00 0,00 0,00

C20:0 2,79 0,03 0,05 0,00 0,00 0,00

C20:l 2,42 0,82 0,74 0,00 0,00 0,00 C20:2N6 0,56 0,05 0,06 0,00 0,00 0,00 C20:3N6 0,67 0,13 0,09 0,00 0,00 0,00 C20:4N6 1,85 0,61 0,56 0,00 0,00 0,00 C20:3N3 3,94 0,07 0,06 0,00 0,00 0,33 C20:4N3 4,32 0,50 0,46 0,00 0,00 0,00 C20:5N3 (EPA) 1,08 29,85 30,09 25,84 15,81 16,35

C22:0 0,00 0,05 0,02 0,00 0,00 0,00

C22:l 2,77 0,00 1,87 0,00 0,00 0,00 C22:2N6 0,00 0,81 0,97 0,00 0,00 0,00 C22:4N6 0,00 0,01 0,02 0,00 0,00 0,00 C22:5N6 1,49 0,01 0,00 0,00 0,00 0,00 C22:5N3 1,48 0,67 0,68 0,00 0,00 0,00 C22:6N3 (DHA) 0,00 10,53 12,49 20,25 16,89 44,63

C24:0 2,34 0,10 0,18 0,00 0,00 0,00

C24:l 0,00 0,25 0,34 0,00 0,00 O5OO

Total 100,00 100,00 100,00 100,00 100,00 100,00

Saturated 25,19 36,46 34,18 43,95 56,47 24,04

Monounsaturated 42,56 14,67 14,29 9,96 10,84 14,65

Polyuns aturated 32,25 48,87 51,53 46,09 32,69 61,31

Total 100,00 100,00 100,00 100,00 100,00 100,00

Omega-3 15,69 44,73 47,73 46,09 32,69 61,31 Omega-6 16,56 4,13 3,81 0,00 0,00 0,00 Table 15. Fatty acid composition of the phosphatidylinositol and phophatidylethanolamine fractions (% (w/w)). Omega-3 0,00 28,40 38,77 0,00 22,15 57,43 Omega-6 0,00 2,67 0,00 0,00 2,62 1,99

Table 16. Compositional data for the novel krill oil composition obtained and NKO krill oil.

EXAMPLE 4

Neutral lipids were extracted from krill meal (138 kg) using SFE with neat CO2 (solvent ratio 25 kg/kg) at 500 bar and 75 °C. The neutral lipids were fractionated at 200 bar (75 0C) and at 60 bar (35 0C) at separator Sl and S2, respectively. The extract obtained in Sl (19,6 kg) were characterized and the results can be found in Tables 17A-C. The extract in table S2 (0,4 kg) were rich in water and were not further used. Next, the polar lipids were extracted using CO2 at 500 bar, 20% ethanol and at a temperature of 75 0C. Using a solvent ratio of 32 (kg/kg) and collecting an extract of 18,2 kg using a separator at 60 bars and 350C. The polar lipids were collected and analyzed (Tables 18A-C). Next, the polar lipids were mixed in a 50/50 ratio with the neutral lipids collected from Sl before finally the ethanol was removed carefully by evaporation. The product obtained was red and transparent. If the ethanol is removed before the mixing if the fractions a transparent product is not obtained. The composition of the 50/50 red and transparent product can be found in Tables 19A-C.

Table 17A Fatty acid composition of the extract collected in Sl

Table 18B. Lipid class composition of the extract collected after CO2 and 20% ethanol in Sl.

Table 18C. Miscellaneous analysis of the extract in Sl.

Table 19A Fatty acid composition of the final blended product obtained in Example 4 in Sl .

EXAMPLE 5

The asta oil obtained in example 1 was blended with the polar lipids obtained in example 4 in a ratio of 46:54 (v/v). Next the ethanol was removed by evaporation and a dark red and transparent product was obtained. The product was analyzed and the results can be found in Tables 20A-C. Furthermore, the product was encapsulated into soft gels successfully. During the encapsulation it was observed that any further increase in phospholipids and thereby viscosity will make it very difficult to encapsulate the final product. Table 2OA Fatty acid composition of the final blended product obtained in Example 5.

EXAMPLE 6

Fresh krill was pumped from the harvesting trawl directly into an indirect steam cooker, and heated to 9OC. Water and a small amount of oil were removed in a screw press before ethoxyquin (antioxidant) was added and the denatured meal was dried under vacuum at a temperature not exceeding 8OC. After 19 months storage in room temperature, a sample of the denatured meal was extracted in two steps with supercritical CO2 in laboratory scale at a flow rate of 2ml/min at IOOC and a pressure of 7500 psi. In the second step 20% ethanol was added to the CO2. The two fractions collected were combined and analyzed by HPLC using ELS detection. The phosphatidylcholine was measured to 42.22% whereas the partly decomposed phosphatidylcholine was 1.68%. This data strongly contrasts the data obtained by analysis of a krill oil sample in the marketplace that showed a content of 9.05% of phosphatidylcholine and 4.60% of partly decomposed phosphatidylcholine.

EXAMPLE 7

Krill lipids were extracted from krill meal (a food grade powder) using supercritical fluid extraction with co-solvent. Initially, 300 bar pressure, 333°K and 5% ethanol (ethanol .'CO2, w/w) were utilized for 60 minutes in order to remove neutral lipids and astaxanthin from the krill meal. Next, the ethanol content was increased to 23% and the extraction was maintained for 3 hours and 40 minutes. The extract was then evaporated using a falling film evaporator and the resulting krill oil was finally filtered. The product obtained was then analyzed and the results can be found in Table 21. Table 21. Analysis of the krill oil obtained using supercritical fluid extraction.

EXAMPLE 8

Krill oil was prepared according to the method described in example 7 extracting from the same krill meal. The oil was subjected to 31P NMR analysis for the identification and quantification of the various forms of phospholipids. The analysis was performed according to the following methods: Samples (20 - 40 mg) were weighed into 1.5 ml centrifuge tubes. Next, NMR detergent (750 μl -10% Na cholate, 1% EDTA, pH 7.0 in H2O+D2O, 0.3 g L-I PMG internal standard) was added. Next, the tube was placed in a oven at 6O0C and periodically shaken/sonicated until completely dispersed. The solution was then transferred to a 5 ml NMR tube for analysis. Phosphorus NMR spectra were recorded on the two-channel Bruker Avance300 with the following instrument settings: spectrometer frequency 121.498MHz, sweep width 24,271 Hz, 64,000 data points, 30 degree excitation pulse, 576 transients were normally taken, each with an 8 second delay time and f.i.d. acquisition time of 1.35 sec. Spectra were processed with a standard exponential weighting function with 0.2 Hz line broadening before Fourier transformation.

Peaks were identified using known chemical shifts. Deacylation of samples with monomethylamine was also used on two samples for confirmation of peak identity and to achieve better peak resolution. Example spectra are presented in Figure 1. Peak area integration gave relative molar amounts of each lipid class. Weight percent values were calculated using molecular masses calculated from a krill sample fatty acid profile (average chain length = 18.6). Total PL levels were calculated from the PMG internal standard peak. The quantification of the phospholipids are shown in table 25 for both the raw material, the final product and for a commercially available krill oil (Neptune Krill Oil). The main polar ether lipids of the krill meal are alkylacylphosphatidylcholine (AAPC) at 7-9 % of total polar lipids, lyso-alkylacylphosphatidylcholine (LAAPC) at 1 % of total polar lipids (TPL) and alkylacylphosphatidyl-ethanolamine (AAPE) at < 1 % of TPL. Table 22 : Phospholipid profiles

Analysis has been carried out on the fatty acid and ether/alcohol profiles of the AAPC. The following results are presented in Table 23.

Table 23. Fatty acid profile of the alkylacylphosphatidylcholine.

AAPC fatty acid AAPC alcohol composition composition alcohol %

20:5(n-3) -

46.9%; 16:0 47.6

22:6(n-3) -

36.1%; 18:1 17.8

18:l(n-9)-4.6% 16:1 14.1

22:5(n-3)-2.6% 14:0 10

20:4(n-6)-1.9% 18:0 8.6

21:5(n-3)-1.5% 18:2 5.1

18:2(n-6)-0.9% 17:0 4.4

16:l(n-9)-0.8% 15:0-i 2.1

16:0-0.7% 15:0 1.7 phytanic - 0.6% 20:1 1.4

18:3(n-3)-0.5% 15:0-a 1.3 18:4(n-3) - 0.4% 18:0-i 0.4 18:l(n-7) - 0.4% 24:1 -0.4% 14:0 - 0.3%

The rest of alcohols (il7:0, etc.), were less than 0.3% each. Only part of 20:1 was confirmed by GC-MS. Alcohol moieties composition of Krill AAPC was determined (identification was performed in the form of l-alkyl-2,3-diTMS glycerols on GC-MS, % of total fatty alcohols were obtained by GC with FID). Ten other fatty acids were all below 0.3 % by mass.

EXAMPLE 9

The purpose of this experiment was to investigate the effect of different omega-3 fatty acid sources on metabolic parameters in the Zucker rat. The Zucker rat is a widely used model, of obesity and insulin resistance. Obesity is due to a mutation in the leptin receptor which impairs the regulation of intake. Omega-3 sources compared in this study were fish oil (FO) and two types of krill oil. The krill oil were either from a commercial supplier (Neptune Krill oil) or prepared according to example 7 (Superba™). Four groups of rats (n = 6 per group) were fed ad lib either a control diet (CTRL) or a diet supplemented with a source of omega-3 fatty acids (FO, NKO, Superba). All diets supplied same amount of dietary fatty acids, oleic acid, linoleic acid and linolenic acid. Omega-3 diets (FO, NKO and Superba™) were additionally balanced for EPA and DHA content. The Zucker rats were 4 wk old at the start of the study with average initial weight of 250 g. At this stage the Zucker rats can be characterized as being pre-diabetic. Rats were fed the test diets for 4 wk after which they were sacrificed and blood and tissue samples were collected. Data presented in the following figures are means ± SE. This example shows that supplementation of the Zucker rat with krill oil prepared as in example 7 results in an improvement of metabolic parameters characteristic of the obesity induced type two diabetic condition. The effect induced by the novel krill oil is often more pronounced than the effect of FO an in several cases greater than the effect induced by NKO. Specifically, the effects of the two types of krill oil differentiated with respect to the reduction of blood LDL cholesterol levels as well as lipid accumulation in the liver and muscle (Figure 2-9). Furthermore, the efficacy of transfer of DHA from the diet to the brain tissue was greatest with the krill oil prepared as in example 7 (Figure 10). EXAMPLE 11

This example describes the effect of the supplementation of human diets with krill oil, fish oil (positive control), or a negative control oil (no omega-3 fatty acids) on blood urea nitrogen (BUN).

BUN measures the amount of nitrogen in the blood that comes from urea. BUN is used as a measure of renal function. Serum creatinine is, however, considered to be a more specific measure of renal function. In this study, krill oil decreased BUN by 11.8% while creatinine levels were unchanged. Thus, it is likely that the decrease in BUN is due to some other effect than improved renal function. BUN decreases if krill oil induced diuresis i.e. excretion of urine (diuretic effect).

BUN also decreases if body protein catabolism is reduced. Protein catabolism is a normal feature of body protein turnover. Many tissues express high protein turnover rates. For example the gastrointestinal system expresses high rates of protein turnover. In growing animals a reduction in GI protein catabolism improves weight gain. Mice supplemented with krill oil grew at a faster rate than mice supplemented with fish oil or control diet (Figure 11).

Table 24. The effect on blood urea nitrogen in humans for the different treatment groups.

Control Krill Oil Menhaden oil p n = 23 n = 24 n = 25 BUN, mg/dL

Baseline 11.5 (7.8, 13.8) 11.5 (9.5, 13.5) 11.5 (9.5, 14.0) 0.523 Δ from baseline, % 11.0 (-14.3, 26.1) -11.8 (-20.0, 1.5) 9.1 (-9.1, 35.7) 0.014r

Creatinine, mg/dL Baseline 0.9 (0.7, 0.9) 0.9 (0.7, 0.9) 0.8 (0.8, 1.0) 0.952r

(r) Δ from baseline, % 0.0 (-9.6, 2.9) 0.0 (-2.0, 5.9) 0.0 (-5.9, 6.7) 0.416

EXAMPLE 12

The purpose of this experiment was to investigate the effect of dietary krill oil on metabolic parameters in high-fat fed mice and to compare the effect of dietary krill oil with that of fish oil containing the same amount of omega-3 fatty acids. Four groups of C57BL/6 mice (n = 10 per group) were fed 1) chow (N), 2) high fat diet comprising 21% butter fat and 0.15% cholesterol (HF), 3) high fat diet + krill oil (HFKO) or 4) high fat diet + fish oil (HFFO). Treatment 3 contained 2.25% (w/w) krill oil as prepared in example 5 (except that the astaxanthin content was 500 ppm) which were equivalent to 0.36% omega-3 fatty acids. Treatment 4 also contained 0.36% omega-3 fatty acids obtained from regular 18-12 fish oil. The diets were fed to the mice for 7 weeks with free access to drinking water. Data represented in this example means ± SE. Columns not sharing a common letter are significantly different (P < 0.05) by ANOVA followed by Tukey's multiple comparison test. N = normal chow diet (n = 10); HF = high-fat diet (n = 10); HFFO = high-fat diet supplemented with fish oil (n = 9); HFKO = high-fat diet supplemented with krill oil (n = 8). The data are presented in Figures 18-25.

This example shows that supplementation of high-fat fed mice with krill oil results in an amelioration of diet-induced hyperinsulinemia, insulin resistance, increase in muscle lipid content (measured as a change in muscle mass), serum adiponectin reduction and hepatic steatosis. These potentially beneficial atheroprotective effects were similar or greater than those achieved with a supplement containing a comparable level of omega-3 fatty acids (Figure 12-19).

Claims

1. A composition comprising: from about 3% to 10% ether phospholipids on a w/w basis; and from about 400 to about 2500 mg/kg astaxanthin.
2. The composition of claim 1, further comprising from about 35% to 50% non-ether phospholipids on w/w basis, so that the total amount of ether phospholipids and non-ether phospholipids in the composition is from about 38% to 60% on a w/w basis.
3. The composition of claim 1 or claim 2, further comprising from about 20% to 45% triglycerides on a w/w basis.
4. The composition of any one of claims 1 to 3, wherein said ether phospholipids are selected from the group consisting of alkylacylphosphatidylcholine, lyso- alkylacylphosphatidylcholine, alkylacylphosphatidylethanolamine, and combinations thereof.
5. The composition of any one of claims 1 to 4, wherein said ether lipids are greater than 90% alkylacylphosphatidylcholine.
6. The composition of any one of claims 1 to 5, wherein said non-ether phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and combinations thereof.
7. The composition of any one of claims 1 to 6, wherein said composition comprises a blend of lipid fractions obtained from Euphausia superba.
8. The composition of any one of claims 1 to 7, wherein said composition comprises from about 25% to 40% omega-3 fatty acids as a percentage of total fatty acids and wherein from about 80% to 90% of said omega-3 fatty acids are attached to said phospholipids.
9. The composition of claim 1, further characterized in comprising at least 65% (w/w) of phospholipids, said phospholipids characterized in containing at least 35% omega-3 fatty acid residues.
10. The composition of any one of claims 1 to 9, wherein the composition is derived from a marine or aquatic biomass.
11. The composition of any one of claims 1 to 9, wherein the composition is derived from krill.
12. The composition of any one of claims 1 to 11, wherein said composition comprises less than 2% free fatty acids.
13. The composition of any one of claims 1 to 12, further characterized in that said phospholipids comprise greater than 50% phosphatidylcholine (w/w).
14. The composition of any one of claims 1 to 12, further characterized in that said phospholipids comprise greater than 70% phosphatidylcholine (w/w).
15. The composition of any one of claims 1 to 12, further characterized in that said phospholipids comprise greater than 80% phosphatidylcholine (w/w).
16. The composition of any one of claims 1 to 15, further characterized in comprising at least 36% (w/w) omega-3 fatty acids.
17. The composition of any one of claims 1 to 16, further characterized in comprising less than about 0.5g/100g total cholesterol.
18. The composition of any one of claims 1 to 17, further characterized in comprising less than about 0.45% arachidonic acid (w/w).
19. The composition of any one of claims 1 to 18, further characterized in being free from acetone.
20. The compositions of any one of claims 1 to 19, wherein said composition is odorless.
21. The composition of any one of claims 1 to 20, wherein said composition comprises less than about 10 mg/kg (w/w) trimethylamine.
22. A composition as claimed in claim 1 wherein said composition is a Euphausia superba •krill oil composition comprising: from about 3% to about 10% w/w ether phospholipids; from about 27% to 50% w/w non-ether phospholipids so that the amount of total phospholipids in the composition is from about 30% to 60% w/w; from about 20% to 50% w/w triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids.
23. A capsule containing the composition of any one of claims 1 to 22.
24. A dietary supplement comprising the composition of any one of claims 1 to 22.
25. A composition as claimed in any one of claims 1 to 22 for the prevention or treatment of diet-induced hyperinsulinemia, insulin insensitivity, muscle mass hypertrophy, serum adiponectin reduction or hepatic steatosis.
26. A composition as claimed in any one of claims 1 to 22 for inducing diuresis.
27. A composition as claimed in any one of claims 1 to 22 for increasing muscle mass.
28. A composition as claimed in any one of claims 1 to 22 for decreasing protein catabolism.
29. A composition as claimed in any one of claims 1 to 22 for prevention or treatment of fatty heart.
30. A composition as claimed in any one of claims 1 to 22 for prevention or treatment of fatty liver.
31. A composition as claimed in any one of claims 1 to 22 for prevention or treatment of insulin resistance, inflammation, blood lipid profile and oxidative stress.
32. A process for producing krill oil comprising: a) providing a denatured krill product; and b) extracting oil from said denatured krill product.
33. The process of claim 32, wherein said denatured krill product is produced by a) providing fresh krill; b) treating said fresh krill to denature Upases and phospholipases in said fresh krill to provide a denatured krill product; and c) extracting oil from said denatured krill product.
34. The process of claim 33 in which the denaturation step comprises heating of said fresh krill.
35. The process of claim 33 in which the denaturation step comprises heating said fresh krill after grinding.
36. The process of any one of claims 32 to 35, further comprising storing said denatured krill product at room temperature or below between the denaturation step and the extraction step.
37. The process of any one of claims 32 to 36, wherein the enzyme denaturation step is achieved by application of heat.
38. The process of any one of claims 32 to 36, wherein said denatured krill product is a krill meal.
39. The process of claim 38, wherein said krill meal is stored prior to said extraction step.
40. The process of any one of claims 32 to 39, wherein the extraction step comprises use of supercritical carbon dioxide, with or without use of a polar modifier.
41. The process of claim 40, wherein said supercritical fluid extraction is a two step process comprising a first extraction step with carbon dioxide and from 1 to 10% of a co- solvent and a second extraction with carbon dioxide and from 10-30% of a co-solvent, wherein said co-solvent is a C1-C3 monohydric alcohol.
42. The process of any one of claims 32 to 41, wherein the extraction step comprises the use of ethanol.
43. The process of any one of claims 32 to 42, wherein the extraction step comprises ethanol extraction followed by acetone whereby to precipitate phospholipids.
44. A process for making a composition as claimed in claim 1 comprising: contacting Euphausia superba with a polar solvent to provide a polar extract comprising phospholipids; contacting Euphasia superba with a neutral solvent to provide a neutral extract comprising triglycerides and astaxanthin; combining said polar extract and said neutral extract to provide Euphausia superba krill oil comprising from about 3% to about 10% w/w ether phospholipids; from about 27% to 50% w/w non-ether phospholipids so that the amount of total phospholipids in the composition is from about 30% to 60% w/w; from about 20% to 50% w/w triglycerides; from about 400 to about 2500 mg/kg astaxanthin; and from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in said composition, wherein from about 70% to 95% of said omega-3 fatty acids are attached to said phospholipids.
45. The process of any one of claims 32 to 44, further comprising encapsulating said krill oil.
46. An oil produced by the processes of any one of claims 32 to 44.
47. A krill lipid extract comprising greater than about 80% triglycerides and greater than about 90 mg/kg astaxanthin esters.
48. The krill lipid extract of claim 47, characterized in containing from about 5% to about 15% omega-3 fatty acid residues.
49. The krill lipid extract of claim 47 or claim 48, characterized in containing less than about 5%-phospholipids.
50. The krill lipid extract of any one of claims 47 to 49, characterized in comprising from about 5% to about 10% cholesterol.
51. A krill meal composition comprising less than about 50g/kg total fat.
52. The krill meal composition of claim 51 comprising from about 5 to about 20 mg/kg astaxanthin esters. -
53. The krill meal composition of claims 51 or 52 comprising greater than about 65% protein.
54. The krill meal composition of any one of claims 51 to 53 comprising greater than about 70% protein.
55. An animal feed comprising the krill meal of any one of claims 51 to 54.
56. Use of the krill meal composition of any one of claims 51 to 54 to increase flesh coloration in an aquatic species.
57. Use of the krill meal composition of any one of claims 51 to 54 to increase growth and overall survival rate of aquatic species.
58. An odorless krill oil produced by the method comprising: extracting a neutral krill oil from a krill oil containing material by supercritical fluid extraction to provide a deodorized krill material, wherein said neutral krill oil contains odor causing compounds; and extracting a polar krill oil from said deodorized krill material by supercritical fluid extraction with a polar entrainer to provide an essentially odorless krill oil.
59. A krill oil produced by the process comprising: pumping fresh krill from a trawl onto a ship, heating the krill to provide a krill material, and extracting oil from the krill material.
PCT/GB2008/001080 2007-03-28 2008-03-28 Bioeffective krill oil compositions WO2008117062A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US92048307 true 2007-03-28 2007-03-28
US60/920,483 2007-03-28
US97505807 true 2007-09-25 2007-09-25
US60/975,058 2007-09-25
US98344607 true 2007-10-29 2007-10-29
US60/983,446 2007-10-29
US2407208 true 2008-01-28 2008-01-28
US61/024,072 2008-01-28

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20080718910 EP2144618B1 (en) 2007-03-28 2008-03-28 Bioeffective krill oil compositions
CA 2682068 CA2682068C (en) 2007-03-28 2008-03-28 Bioeffective krill oil compositions
ES08718910T ES2415684T3 (en) 2007-03-28 2008-03-28 Oil compositions of biologically effective krill
DK08718910T DK2144618T3 (en) 2007-03-28 2008-03-28 Bioeffektive krill oil compositions

Publications (1)

Publication Number Publication Date
WO2008117062A1 true true WO2008117062A1 (en) 2008-10-02

Family

ID=39577593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001080 WO2008117062A1 (en) 2007-03-28 2008-03-28 Bioeffective krill oil compositions

Country Status (6)

Country Link
US (12) US9034388B2 (en)
EP (2) EP2612672A1 (en)
CA (1) CA2682068C (en)
DK (1) DK2144618T3 (en)
ES (1) ES2415684T3 (en)
WO (1) WO2008117062A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094823A1 (en) * 2006-11-16 2009-09-02 Pronova Biopharma Norge AS Process for production of omega-3 rich marine phospholipids from krill
WO2010097699A1 (en) * 2009-02-26 2010-09-02 Aker Biomarine Asa Phospholipid and protein tablets
WO2010097701A1 (en) * 2009-02-26 2010-09-02 Aker Biomarine Asa Low viscosity phospholipid compositions
KR100992995B1 (en) 2010-05-03 2010-11-09 연세대학교 산학협력단 Novel uses of piperonal
WO2011018096A1 (en) * 2009-08-10 2011-02-17 K.D. Pharma Bexbach Gmbh Phytanic acid fractionation process, fatty acid products and use thereof
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
WO2010136900A3 (en) * 2009-05-28 2011-06-16 Aker Biomarine Asa Methods of using krill oil to treat risk factors for metabolic disorders and obesity
DE202011050351U1 (en) 2010-06-04 2011-11-24 Sana Pharma As Dietary products or formulations
WO2011124895A3 (en) * 2010-04-09 2012-11-22 Ayanda Group As Phospholipid-containing pharmaceutical and nutraceutical compositions
WO2012172411A1 (en) * 2011-06-15 2012-12-20 Stable Solutions Llc Therapeutic application of parenteral krill oil
WO2013136183A2 (en) 2012-03-12 2013-09-19 Innolipid, As Oxidixable fatty acid composition delivery form
US8609157B2 (en) 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
WO2014013335A2 (en) 2012-07-17 2014-01-23 Aker Biomarine As Concentration of omega-3 polyunsaturated fatty acids in krill oil
WO2014045127A2 (en) 2012-09-19 2014-03-27 Aker Biomarine As Omega-3 phospholipid supplements for females
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US8784921B2 (en) 2008-09-26 2014-07-22 Nippon Suisan Kaisha, Ltd. Method for concentrating lipids
WO2014140873A2 (en) 2013-03-14 2014-09-18 Aker Biomarine As Omega- 3 phospholipid supplements for improved brain maturity
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN102603791B (en) * 2012-02-21 2014-12-24 山东师范大学 Preparation method of Antarctic krill phosphatidyl ethanolamine product
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes
WO2016128838A2 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid compositions
EP2988759A4 (en) * 2013-03-14 2016-11-30 Inst Rech Sur Les Zones Cotieres Irzc Method for extracting organic solids and oil from marine organisms enriched with astaxanthin
WO2016190748A1 (en) 2015-05-27 2016-12-01 Rimfrost As A flowable concentrated phospholipid krill oil composition
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334199B1 (en) 2008-09-12 2017-06-28 Rimfrost Technologies AS Process for reducing the fluoride content when producing proteinaceous concentrates from krill
US8557297B2 (en) 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
WO2010077152A1 (en) * 2009-01-05 2010-07-08 Calanus As Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease
JP2012529503A (en) * 2009-06-12 2012-11-22 カラナス エーエス Oil compositions, formulations comprising an oil composition, and reduce the accumulation of visceral fat, its use for the prevention or treatment of obesity-related diseases and disorders to improve glucose tolerance
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US8273248B1 (en) 2010-04-06 2012-09-25 Heliae Development, Llc Extraction of neutral lipids by a two solvent method
CA2794106A1 (en) 2010-04-06 2011-10-13 Heliae Development, Llc Methods of and systems for dewatering algae and recycling water therefrom
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
JP5271454B2 (en) * 2010-09-01 2013-08-21 日本水産株式会社 Alcohol disorders emollients
US20120231087A1 (en) 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
EP2697345B1 (en) * 2011-04-14 2016-03-23 Polar Omega A/S A process for the isolation of a phospholipid
CN103608022A (en) * 2011-05-31 2014-02-26 日本水产株式会社 To improve brain function
WO2013075116A3 (en) 2011-11-17 2013-11-07 Heliae Development, Llc Omega 7 rich compositions and methods of isolating omega 7 fatty acids
WO2013086323A3 (en) * 2011-12-08 2015-07-09 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
WO2014057362A3 (en) * 2012-09-24 2014-11-20 Aker Biopharma As Omega -3 compositions
WO2014060847A1 (en) * 2012-09-24 2014-04-24 Aker Biopharma As Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
WO2014207571A3 (en) * 2013-06-14 2015-04-30 Aker Biomarine Antarctic As Lipid extraction processes
WO2017031502A1 (en) * 2015-08-20 2017-02-23 Avoca, Inc. Method for increasing muscle growth using krill extract

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4119619A (en) * 1976-12-16 1978-10-10 Sergei Vasilievich Rogozhin Emulsification method for the processing of kriel to produce protein, lipids and chitin
WO2000023546A1 (en) * 1998-10-21 2000-04-27 Universite De Sherbrooke Method of extracting lipids from marine and aquatic animal tissues
EP1127497A1 (en) * 1998-11-02 2001-08-29 Nippon Suisan Kaisha, Ltd. Dry krill powder
WO2002102394A2 (en) * 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
WO2003011873A2 (en) 2001-07-27 2003-02-13 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2652235A (en) * 1951-11-29 1953-09-15 Beatrice L Samuelsen Heating attachment for electric food mixers
GB921537A (en) 1959-05-22 1963-03-20 Mario Meroni Process for extracting fatty substances from animal material
JPS58850B2 (en) 1975-03-14 1983-01-08 Nichiro Gyogyo Kk
JPS5743214B2 (en) 1975-04-25 1982-09-13
JPS537508B2 (en) * 1975-04-25 1978-03-18
JPS5842741B2 (en) 1976-03-19 1983-09-21 Nikken Chemicals Co Ltd
US4133077A (en) 1976-09-14 1979-01-09 Prezedsiebiorstwo Polowow Dalekomorskich i Uslug Rybackich "Dalmor" Method for obtaining of meat from marine crustacea, especially from Antarctic krill
CA1098900A (en) 1977-12-14 1981-04-07 Sergei V. Rogozhin Method for the processing of krill to produce protein, lipids and chitin
JPS5636909B2 (en) * 1978-06-12 1981-08-27
WO1982002819A1 (en) 1981-02-16 1982-09-02 Hansen Bent Schiott A food product on the basis of fish flesh and a process for the preparation thereof
GB2097014B (en) 1981-04-13 1984-08-01 Baikoff Eugene Marc Alexandre Ultrasonic extraction of vegetable oil
US4505936A (en) * 1983-09-14 1985-03-19 Louisiana State University Process for the utilization of shellfish waste
JPS60153779A (en) 1984-01-24 1985-08-13 Hohnen Oil Co Ltd Nutrient-assisting food
US4814111A (en) 1984-02-13 1989-03-21 Air Products And Chemicals, Inc. Process for purification of phospholipids
US4714571A (en) * 1984-02-13 1987-12-22 The Liposome Company, Inc. Process for purification of phospholipids
US5006281A (en) * 1985-03-26 1991-04-09 Century Laboratories, Inc. Process for the production of a marine animal oil
DK157452C (en) 1985-04-12 1990-05-21 Matcon Radgivende Ing Firma A process for recovering chitin from chitinkilder in which it is present together with or bound to the protein substances
JPS6340827B2 (en) 1985-06-06 1988-08-12 Shiseido Kk
US4749522A (en) 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
JPS6323819A (en) 1986-07-16 1988-02-01 Kao Corp Inhibitor of blood platelet aggregation
EP0393035B1 (en) 1987-08-06 1995-06-21 Aktiebolaget L.H. Forskning Method for the isolation of active enzyme(s) from krill tissue
JP2524217B2 (en) 1988-04-18 1996-08-14 マルハ株式会社 Brain function improving composition, learning ability enhancing agent, a storage strength agents, dementia prophylactic or dementia therapeutic agents
WO1989010960A1 (en) 1988-05-05 1989-11-16 Pharmacia Ab Method for modifying proteins, peptides and/or lipids by enzymes from euphauciaceae
JP2619491B2 (en) 1988-08-11 1997-06-11 サントリー株式会社 Astaxanthin-containing composition
US5210186A (en) 1988-11-18 1993-05-11 Mikalsen Gunnar Method for recovery and separation of chitin, proteins and astaxanthin and esters thereof
JP2909508B2 (en) 1989-02-14 1999-06-23 マルハ株式会社 Preparative Method of krill phospholipids
DE3918082C2 (en) * 1989-06-02 1992-02-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften Ev, 3400 Goettingen, De
JPH0381692A (en) 1989-08-23 1991-04-08 Hitachi Ltd Fuel supply device of magnetic field confinment type nuclear fusion device
JP2861246B2 (en) 1990-04-26 1999-02-24 松下電器産業株式会社 Switching power supply unit
JP2963152B2 (en) 1990-06-28 1999-10-12 イタノ冷凍株式会社 Extraction separation method of the dye from krill
DE69232564D1 (en) * 1991-05-30 2002-05-23 Fresenius Kabi Ab Uppsala phospholipids
JP3081692B2 (en) 1991-11-28 2000-08-28 イタノ冷凍株式会社 Extraction separation method of the dye from krill
CA2136331C (en) 1992-05-22 2005-08-30 Ragnvald Lindblom New pharmaceutical uses of krill enzymes
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JP3467794B2 (en) 1993-03-09 2003-11-17 日本油脂株式会社 Learning ability improver
JP3486778B2 (en) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 Alzheimer's disease prevention treatment agent
US6555155B2 (en) 1996-10-21 2003-04-29 Biozyme Systems, Inc. Method and apparatus for harvesting, digestion and dehydrating of krill hydrolysates and co-drying and processing of such hydrolysates
JPH07242621A (en) 1994-03-02 1995-09-19 Nippon Oil Co Ltd Method for extracting carotenoid compound
FR2731015B1 (en) * 1995-02-24 1997-05-30 Sci Sartone Method for enzymatic enrichment marine oils and triglycerides of polyunsaturated fatty acids thus obtained
JPH08231391A (en) 1995-02-24 1996-09-10 Fuji Yakuhin:Kk Dementia-improving medicine
JP3344887B2 (en) 1995-12-22 2002-11-18 池田食研株式会社 The method of concentrating polyunsaturated fatty acid-containing oil
JP3611222B2 (en) 1996-01-26 2005-01-19 池田食研株式会社 Peroxide polyunsaturated fatty acids containing oil reduction method
US5672370A (en) 1996-04-16 1997-09-30 The University Of British Columbia Method of producing a dried krill product
WO1997039759A3 (en) 1996-04-24 1998-01-15 Brigham & Womens Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
JP3678317B2 (en) 1996-05-21 2005-08-03 クロリンエンジニアズ株式会社 Method for concentrating eicosapentaenoic acid content
FR2757021B1 (en) * 1996-12-17 1999-01-22 Sea Oil Method and fish oil extraction plant and the products
CA2197137A1 (en) 1997-02-07 1998-08-07 Biozyme Systems Inc. Method and apparatus for co-drying krill hydrolysate, liquid marine protein and dry carrier
JP2000513738A (en) 1997-02-23 2000-10-17 アイ・ビー・アール−イスラエリ バイオテクノロジー リサーチ リミテッド Antiproliferative preparations
JP3408958B2 (en) * 1997-10-24 2003-05-19 旭化成株式会社 Processes for making compositions and their useful materials containing useful substances derived from fish
US20030113432A1 (en) * 1998-11-02 2003-06-19 Nippon Suisan Kaisha, Ltd. Process for making dried powdery and granular krill
WO2000038708A9 (en) 1998-12-24 2000-12-07 Phairson Medical Inc Treatment and prevention of immune rejection reactions
DE60008276D1 (en) 1999-10-21 2004-03-18 Truffini & Regge Farmaceutici Enteric tablet for food, diet and therapy
JP2001158736A (en) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd Agent for preventing and improving osteoarthropathy
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
EP1272049B1 (en) 2000-04-12 2009-11-04 GEA Westfalia Separator GmbH Method for the fractionation of oil and polar lipid-containing native raw materials using alcohol and centrifugation
EP2319508A1 (en) 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
KR20030096312A (en) 2001-04-11 2003-12-24 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Fatty alcohols and fatty acid esters useful for treatment of inflammation
CA2451116C (en) 2001-05-14 2013-04-09 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
JP2003003192A (en) 2001-06-20 2003-01-08 Unitika Ltd Method for extracting sphingolipid or sphingoglycolipid
WO2003003857A1 (en) 2001-07-04 2003-01-16 Angulas Aguinaga, S.A. Method of obtaining thermoformed products using dense and liquid antarctic krill fractions
CA2456049C (en) 2001-08-02 2012-10-16 Suntory Limited Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
JP4568464B2 (en) 2001-11-07 2010-10-27 雪印乳業株式会社 Memory disorders prophylactic treatment agent
US20060057185A1 (en) 2002-09-24 2006-03-16 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
EP1569525A1 (en) 2002-11-26 2005-09-07 Phares Pharmaceutical Research N.V. Marine lipid compositions
US7488503B1 (en) 2003-03-31 2009-02-10 Mccormick & Company, Inc. Encapsulation compositions and processes for preparing the same
EP1637151A1 (en) * 2003-04-11 2006-03-22 Kyowa Hakko Kogyo Co., Ltd. Preventive or remedy for arthritis
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
EP1633335A4 (en) 2003-06-19 2009-08-19 Advanced Bionutrition Corp Improved absorption of fat-soluble nutrients
KR20060028482A (en) 2003-07-03 2006-03-29 코닌클리케 필립스 일렉트로닉스 엔.브이. Secure indirect addressing
RU2298319C2 (en) 2003-07-15 2007-05-10 Акер Сифудз Холдинг Ас Trawl construction
US7964641B2 (en) 2003-08-18 2011-06-21 Btg International Limited Treatment of neurodegenerative conditions
WO2005038037A3 (en) 2003-10-22 2005-12-01 Enzymotec Ltd Methods for preparing phospholipids containing omega-3 and omega-6 moieties
CA2542504C (en) 2003-10-22 2014-01-07 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
ES2329809T3 (en) 2004-01-21 2009-12-01 Tiberio Bruzzese Use of highly concentrated compositions of n-3 fatty acids selected for treatment of central nervous system disorders.
JP2005245379A (en) 2004-03-08 2005-09-15 Nippon Suisan Kaisha Ltd Aggregate of eyeball of crustaceans, method for using the same, food containing the same, and method for producing the same
JP2006069948A (en) 2004-09-01 2006-03-16 Yukihiro Hirose Anti-aging composition and cosmetics, beverages and foods containing the same
JP2006083136A (en) 2004-09-17 2006-03-30 Suntory Ltd Composition having action for preventing or ameliorating lowering of cerebral function caused by stress and symptom or disease involving the same lowering
US7666447B2 (en) * 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
JP2006290784A (en) 2005-04-08 2006-10-26 Yukihiro Hirose Composition having bloodstream aggravation-preventing action and food and beverage containing the same composition
WO2006111633A3 (en) 2005-04-18 2007-04-05 Sc Dicophar Use of lecithin as a medicament for treating psoriasis
JP2006328014A (en) 2005-05-30 2006-12-07 Yukihiro Hirose Composition having prevention action on blood flow deterioration
JP2007126455A (en) 2005-10-07 2007-05-24 Fuji Chem Ind Co Ltd Cerebral dysfunction improving agent
WO2007080514A3 (en) 2006-01-13 2007-10-18 Krill As A method for the extraction of lipid fractions from krill
WO2007080515A1 (en) 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
JP2007246404A (en) 2006-03-14 2007-09-27 Snow Brand Milk Prod Co Ltd Learning ability-improving agent
WO2007108702A1 (en) 2006-03-23 2007-09-27 Aker Seafoods Holding As A trawl device
WO2007123424A1 (en) 2006-04-20 2007-11-01 Owen John Catchpole Process for separating lipid materials
KR101484656B1 (en) 2006-05-24 2015-01-21 인더스트리얼 리서치 리미티드 Extraction of highly unsaturated lipids with liquid dimethyl ether
JP5827784B2 (en) 2006-07-14 2015-12-02 ナットファルマ エーエスエー Pharmaceutical and nutraceutical products containing vitamin k2
EP2094823A4 (en) 2006-11-16 2011-02-02 Pronova Biopharma Norge As Process for production of omega-3 rich marine phospholipids from krill
WO2008072563A1 (en) 2006-12-11 2008-06-19 Nippon Suisan Kaisha, Ltd. Feed using peeled krill as the starting material and method of preventing decrease in fish growth rate by using the same
US20080166420A1 (en) 2007-01-04 2008-07-10 Sones Scott F Krill Oil Compositions
US20080166419A1 (en) * 2007-01-04 2008-07-10 Sones Scott F Krill oil compositions
CA2682068C (en) 2007-03-28 2017-11-28 Aker Biomarine Asa Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20080268117A1 (en) 2007-04-30 2008-10-30 David Rubin Method of purifying oils containing epa and dha
EP2732709A1 (en) 2007-08-29 2014-05-21 Aker BioMarine AS A new method for making krill meal
US20100226977A1 (en) 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
KR20110021886A (en) 2008-05-15 2011-03-04 프로노바 바이오파마 노르지 에이에스 Krill oil process
US8557297B2 (en) 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2010097701A1 (en) 2009-02-26 2010-09-02 Aker Biomarine Asa Low viscosity phospholipid compositions
US8586567B2 (en) 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
CN102638998B (en) 2009-10-30 2015-10-07 塞拉斯有限责任公司 For obtaining phospholipid-rich krill oil and neutral fat-free solvent extraction method
US20110223246A1 (en) 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011130487A1 (en) 2010-04-14 2011-10-20 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
KR101835326B1 (en) 2010-09-26 2018-03-07 엘지전자 주식회사 Method and apparatus for efficient feedback in a wireless communication system supporting multiple antenna
EP2697345B1 (en) 2011-04-14 2016-03-23 Polar Omega A/S A process for the isolation of a phospholipid
EP2825057A2 (en) 2012-03-12 2015-01-21 Aker Biomarine Antarctic As Oxidixable fatty acid composition delivery form
CA2878786A1 (en) 2012-07-17 2014-01-23 Aker Biomarine Antarctic As Concentration of omega-3 polyunsaturated fatty acids in krill oil
CN102746941B (en) 2012-07-18 2014-01-15 山东师范大学 Method for enriching phosphatidyl inositol from antarctic krill
WO2014045127A3 (en) 2012-09-19 2014-06-05 Aker Biomarine As Omega-3 phospholipid supplements for females
WO2014057362A3 (en) 2012-09-24 2014-11-20 Aker Biopharma As Omega -3 compositions
WO2014060847A1 (en) 2012-09-24 2014-04-24 Aker Biopharma As Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
WO2014140873A3 (en) 2013-03-14 2015-07-30 Aker Biomarine Antarctic As Omega- 3 phospholipid supplements for improved brain maturity
WO2014207571A3 (en) 2013-06-14 2015-04-30 Aker Biomarine Antarctic As Lipid extraction processes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4119619A (en) * 1976-12-16 1978-10-10 Sergei Vasilievich Rogozhin Emulsification method for the processing of kriel to produce protein, lipids and chitin
WO2000023546A1 (en) * 1998-10-21 2000-04-27 Universite De Sherbrooke Method of extracting lipids from marine and aquatic animal tissues
US6800299B1 (en) 1998-10-21 2004-10-05 Universite De Sherbrooke Method of extracting lipids from marine and aquatic animal tissues
EP1127497A1 (en) * 1998-11-02 2001-08-29 Nippon Suisan Kaisha, Ltd. Dry krill powder
WO2002102394A2 (en) * 2001-06-18 2002-12-27 Neptune Technologies & Bioressources Inc. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
WO2003011873A2 (en) 2001-07-27 2003-02-13 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SAETHER ET AL., COMP. BIOCHEM PHYS. B, vol. 83B, no. 1, 1986, pages 51 - 55
TANAKA ET AL., J. OLEO SCI., vol. 53, no. 9, 2004, pages 417 - 424
YAMAGUCHI ET AL., J AGRIC. FOOD CHEM., vol. 34, no. 5, 1986, pages 904 - 7
YAMAGUCHI K ET AL: "Supercritical carbon dioxide extraction of oils from antarctic krill", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 34, 1 January 1986 (1986-01-01), pages 904 - 907, XP002430955, ISSN: 0021-8561 *

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094823A4 (en) * 2006-11-16 2011-02-02 Pronova Biopharma Norge As Process for production of omega-3 rich marine phospholipids from krill
EP2094823A1 (en) * 2006-11-16 2009-09-02 Pronova Biopharma Norge AS Process for production of omega-3 rich marine phospholipids from krill
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9816046B2 (en) 2007-03-28 2017-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9034388B2 (en) 2007-03-28 2015-05-19 Aker Biomarine Antartic As Bioeffective krill oil compositions
US9730966B2 (en) 2007-03-28 2017-08-15 Aker Biomarine Antartic As Method of reducing appetite in a human subject comprising administering krill oil composition
US9028877B2 (en) 2007-03-28 2015-05-12 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9889163B2 (en) 2007-03-28 2018-02-13 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9644169B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9644170B2 (en) 2007-03-28 2017-05-09 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9375453B2 (en) 2007-03-28 2016-06-28 Aker Biomarine Antarctic As Methods for producing bioeffective krill oil compositions
US9320765B2 (en) 2007-03-28 2016-04-26 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9220735B2 (en) 2007-03-28 2015-12-29 Aker Biomarine Antarctic As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US9078905B2 (en) 2007-03-28 2015-07-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9072752B1 (en) 2007-03-28 2015-07-07 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US9119864B2 (en) 2007-03-28 2015-09-01 Aker Biomarine Antarctic As Bioeffective krill oil compositions
US8784921B2 (en) 2008-09-26 2014-07-22 Nippon Suisan Kaisha, Ltd. Method for concentrating lipids
WO2010097701A1 (en) * 2009-02-26 2010-09-02 Aker Biomarine Asa Low viscosity phospholipid compositions
WO2010097699A1 (en) * 2009-02-26 2010-09-02 Aker Biomarine Asa Phospholipid and protein tablets
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2010136900A3 (en) * 2009-05-28 2011-06-16 Aker Biomarine Asa Methods of using krill oil to treat risk factors for metabolic disorders and obesity
WO2011018096A1 (en) * 2009-08-10 2011-02-17 K.D. Pharma Bexbach Gmbh Phytanic acid fractionation process, fatty acid products and use thereof
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
KR101788342B1 (en) * 2009-10-29 2017-10-19 아카스티 파마, 인크. Concentrated therapeutic phospholipid compositions
JP2015147793A (en) * 2009-10-29 2015-08-20 アカスティ ファーマ インコーポレイテッド concentrated therapeutic phospholipid composition
JP2013508431A (en) * 2009-10-29 2013-03-07 アカスティ ファーマ インコーポレイテッド Concentrated therapeutic phospholipid compositions
US8586567B2 (en) 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
RU2642653C2 (en) * 2009-10-29 2018-01-25 Акасти Фарма, Инк. Concentrated therapeutic phospholipide compositions
US9475830B2 (en) 2009-10-29 2016-10-25 Acasti Pharma Inc. Concentrated therapeutic phospholipid compositions
US8609157B2 (en) 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8772516B2 (en) 2009-10-30 2014-07-08 Tharos. Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US8865236B2 (en) 2009-10-30 2014-10-21 Tharos Ltd. Solvent-Free Process for Obtaining Phospholipids and Neutral Enriched Krill Oils
US9011942B2 (en) 2009-10-30 2015-04-21 Tharos, Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
US9150815B2 (en) 2009-10-30 2015-10-06 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
WO2011124895A3 (en) * 2010-04-09 2012-11-22 Ayanda Group As Phospholipid-containing pharmaceutical and nutraceutical compositions
KR100992995B1 (en) 2010-05-03 2010-11-09 연세대학교 산학협력단 Novel uses of piperonal
DE202011050351U1 (en) 2010-06-04 2011-11-24 Sana Pharma As Dietary products or formulations
WO2011151632A1 (en) 2010-06-04 2011-12-08 Sana Pharma As Dietary formulations
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
WO2012172411A1 (en) * 2011-06-15 2012-12-20 Stable Solutions Llc Therapeutic application of parenteral krill oil
RU2625760C2 (en) * 2011-06-15 2017-07-18 СТЕЙБЛ СОЛЮШНЗ ЭлЭлСи Therapeutic application of krill oil
US9458409B2 (en) 2011-09-02 2016-10-04 Arctic Nutrition As Lipid compositions with high DHA content
US8846604B2 (en) 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
CN102603791B (en) * 2012-02-21 2014-12-24 山东师范大学 Preparation method of Antarctic krill phosphatidyl ethanolamine product
WO2013136183A2 (en) 2012-03-12 2013-09-19 Innolipid, As Oxidixable fatty acid composition delivery form
WO2014013335A2 (en) 2012-07-17 2014-01-23 Aker Biomarine As Concentration of omega-3 polyunsaturated fatty acids in krill oil
WO2014045127A2 (en) 2012-09-19 2014-03-27 Aker Biomarine As Omega-3 phospholipid supplements for females
EP2988759A4 (en) * 2013-03-14 2016-11-30 Inst Rech Sur Les Zones Cotieres Irzc Method for extracting organic solids and oil from marine organisms enriched with astaxanthin
WO2014140873A2 (en) 2013-03-14 2014-09-18 Aker Biomarine As Omega- 3 phospholipid supplements for improved brain maturity
US9295683B2 (en) 2013-03-14 2016-03-29 Aker Biomarine Antarctic As Omega-3 phospholipid supplements for improved brain maturity
US9867856B2 (en) 2014-01-10 2018-01-16 Aker Biomarine Antarctic As Phospholipid compositions and their preparation
WO2016128838A2 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid compositions
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes
WO2016190748A1 (en) 2015-05-27 2016-12-01 Rimfrost As A flowable concentrated phospholipid krill oil composition

Also Published As

Publication number Publication date Type
US20150004227A1 (en) 2015-01-01 application
CA2682068C (en) 2017-11-28 grant
US20170246219A1 (en) 2017-08-31 application
US9072752B1 (en) 2015-07-07 grant
US9889163B2 (en) 2018-02-13 grant
US20170240842A1 (en) 2017-08-24 application
EP2144618B1 (en) 2013-05-15 grant
US9320765B2 (en) 2016-04-26 grant
US9644169B2 (en) 2017-05-09 grant
US9644170B2 (en) 2017-05-09 grant
US9816046B2 (en) 2017-11-14 grant
US20160279173A1 (en) 2016-09-29 application
DK2144618T3 (en) 2013-06-17 grant
US9034388B2 (en) 2015-05-19 grant
EP2612672A1 (en) 2013-07-10 application
US20080274203A1 (en) 2008-11-06 application
US20150004223A1 (en) 2015-01-01 application
US9375453B2 (en) 2016-06-28 grant
US20160281026A1 (en) 2016-09-29 application
US20170239300A1 (en) 2017-08-24 application
US20150157669A1 (en) 2015-06-11 application
US9028877B2 (en) 2015-05-12 grant
US20150164963A1 (en) 2015-06-18 application
US9078905B2 (en) 2015-07-14 grant
ES2415684T3 (en) 2013-07-26 grant
US9119864B2 (en) 2015-09-01 grant
CA2682068A1 (en) 2008-10-02 application
US20140010888A1 (en) 2014-01-09 application
US20140005421A1 (en) 2014-01-02 application
EP2144618A1 (en) 2010-01-20 application

Similar Documents

Publication Publication Date Title
Kobatake et al. Differential Effects of Dietary Eicosapentaenoic and Docosahexaenoic Fatty Acids on Lowering of Tri-glyceride and Cholesterol Levels in the Serum of Rats on Hypercholesterolemic Diet
Bell et al. Effects of broodstock dietary lipid on fatty acid compositions of eggs from sea bass (Dicentrarchus labrax)
US5880300A (en) Phospholipid-based removal of sterols from fats and oils
Torstensen et al. Tailoring of a cardioprotective muscle fatty acid composition of Atlantic salmon (Salmo salar) fed vegetable oils
Leigh-Firbank et al. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses
Dyerberg et al. Bioavailability of marine n-3 fatty acid formulations
Schuchardt et al. Bioavailability of long-chain omega-3 fatty acids
US20110268811A1 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
Kanazawa et al. Dietary hydroperoxides of linoleic acid decompose to aldehydes in stomach before being absorbed into the body
US20060217356A1 (en) Nutritional supplement for lowering serum triglyceride and cholesterol levels
Fu et al. Increased α-linolenic acid intake increases tissue α-linolenic acid content and apparent oxidation with little effect on tissue docosahexaenoic acid in the guinea pig
US6998501B1 (en) Nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030225160A1 (en) Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications
Burdge et al. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13 C] α-linolenic acid to longer-chain fatty acids and partitioning towards β-oxidation in older men
Palozza et al. n–3 Fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation
Charnock et al. Comparative changes in the fatty-acid composition of rat cardiac phospholipids after long-term feeding of sunflower seed oil-or tuna fish oil-supplemented diets
US20070004678A1 (en) Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
Ayerza Jr et al. Effect of dietary α-linolenic fatty acid derived from chia when fed as ground seed, whole seed and oil on lipid content and fatty acid composition of rat plasma
US20130059768A1 (en) Lipid compositions with high dha content
WO2005037848A2 (en) Glycerophospholipids containing omega-3 and omega-6 fatty acids
Calviello et al. Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues
US6303803B1 (en) Removal of sterols from fats and oils
US20060052351A1 (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress
Henna Lu et al. Oxidative stability of marine phospholipids in the liposomal form and their applications
Njinkoué et al. Lipids and fatty acids in muscle, liver and skin of three edible fish from the Senegalese coast: Sardinella maderensis, Sardinella aurita and Cephalopholis taeniops

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08718910

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2682068

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008231570

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2008231570

Country of ref document: AU

Date of ref document: 20080328

Kind code of ref document: A